
MFT TRUST FORMULARY



	BNF Chapter
Section 1:	Gastro-Intestinal System
Section 2:	Cardiovascular System
Section 3:	Respiratory System
Section 4:	Central Nervous System
Section 5:	Infections
Section 6:	Endocrine System
Section 7:	Obstetrics, gynaecology & urinary tract disorders
Section 8:	Malignant disease & immunosuppression
Section 9:	Nutrition & blood
Section 10:	Musculoskeletal & Joint Diseases
Section 11:	Eye
Section 12:	Ear, nose & oropharynx
Section 13:	Skin
Section 14:	Immunological products & vaccines
Section 15:	Anaesthesia
Section 16:	Miscellaneous

Version 10.5 (May 2025)



Prescribers must always bear in mind when prescribing medicines recommended as "treatment options" by NICE, that this is an opportunity for the clinician and the patient to consider and discuss its use alongside other potential treatment options available.

Formulary status definitions

Formulary (OK to be prescribed - but after any 1st or 2nd line options)

1st line formulary (when there are few formulary options, this is the 1st choice)

2nd line formulary (when there are few formulary options, this is the 2nd choice)

Where there is no preferred 1st line agent provided, the drug choice appears in alphabetical order.

1st line medicines for certain therapeutic groups and any restrictions placed upon prescribing are indicated in the box after the medicine name. Where modified release preparations of a formulary drug are available a comment will clarify its status. Newly licensed modified release preparations of existing formulary drugs will remain non-formulary until a review is carried out and recommendations are published. Where published guidance from NICE, MTRAC or the CSM is available, a reference to this is made either in the box after the medicine name or under the section title. Prescribing guidance issued by the Area Prescribing Committee is also included where it is available.



GMMMG Red/Amber/Green classifications



RED

Drugs considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy or specialist service. This may include arranging for supply via a home care company.

AMBER

Drugs suitable for shared care arrangements under a shared care protocol.

Prescribing and monitoring responsibilities may be transferred from specialist teams to primary care prescribers in line with a shared care protocol. Shared care arrangements will usually be supported by a GMMMG shared care protocol (SCP).

See here for a list of GMMMG approved SCPs.

GREEN

Drugs that are suitable for initiation and ongoing prescribing within primary care.

SA

Green following specialist advice. Drugs that are suitable for initiation by primary care following written or verbal advice from a specialist service. Little or no monitoring is required.

SI

Green following specialist initiation. Drugs that are suitable for ongoing prescribing within primary care following initiation by a specialist service. Little or no monitoring is required.

(DNP)

Products which are not recommended for prescribing in any setting. "Do Not Prescribe" status may relate to a specific medicine, or to prescribing for a particular indication. This is in addition to all medicines with a "not NHS" or "Drugs of Low Clinical Value" classification in the BNF, and those medicines with a NICE "Do not do" recommendation.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety concerns.

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation.

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

GREY

Products which are not suitable for routine prescribing but suitable for exceptional use in a defined patient population. Prescribers should ensure that more suitable alternatives have been considered and ruled out as not being appropriate before recommending or prescribing a medicine with a GREY list status. In these cases a RAG of RED, AMBER or GREEN will also be assigned to clarify in which care setting prescribing responsibility lies.

Criteria for inclusion on DNP/grey lists:

Criterion 1: Products of low clinical effectiveness, where there is a lack of robust evidence of clinical effectiveness or there are significant safety

Criterion 2: Products which are clinically effective but where more cost-effective products are available, including products that have been subject to excessive price inflation

Criterion 3: Products which are clinically effective but, due to the nature of the product or condition being treated, are deemed a low priority for NHS funding.

OTC

In line with NHS England guidance, GM do not routinely support prescribing for conditions which are self-limiting or amenable to self-care.



Unlicensed indications are automatically classified as red unless designated otherwise on the list below. If a medicine is unlicensed this should be annotated as follows: drug name $\overline{\mathbb{Q}}$

Formulary symbols

MMC	Medicines Management Committee decisions
emc⊚	Electronic medicines compendium (SmPC & PIL)
BNF	British National Formulary (BNF)
BNF for children	British National Formulary for Children (BNFC)
NICE	NICE guidance
PbR X	NHS Payment Scheme (NHSPS) excluded medicine (previously known as PbR excluded)
<u>ca</u>	Controlled Drug
0	Unlicensed medicine
££	High cost medicine
blueteq	Blueteq enabled forms
MedTeq	MedTeq Enabled Forms
NOT STOCKED	Not routinely stocked, can be ordered if existing patient supply is exhausted

PCT Guidelines

Greater Manchester Medicines Management Group FORMULARY

GMMMG

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

GMMMG Approved Shared Care Protocols

Useful Links

All Wales Medicines Strategy Group

British HIV Association (BHIVA)

British National Formulary (No password required)

British National Formulary for Children (No password required)

Commission on Human Medicines (CHM)

electronic Medicines Compendium (eMC)

General Pharmaceutical Council (GPhC)

Greater Manchester Medicines Management Group (GMMMG)

Medicines and Healthcare products Regulatory Agency (MHRA)

Midlands Therapeutics Review and Advisory Committee (MTRAC)

National Institute for Health and Clinical Excellence (NICE)

Scottish Medicines Consortium (SMC)

Specialist Pharmacist Service (SPS)

Section 1: Gastro-Intestinal system

Supported by the formulary (click here)



1.1 Dyspepsia & gastro-oesophageal reflux disease

- 1.1.1 Antacids & Simeticone
- 1.1.2 Compound Alginates & Proprietary Indigestion Preparations

1.2 Anti-spasmodics & other drugs altering gut motility

Antimuscarinics Other Antispasmodics Motility Stimulants

1.3 Antisecretory drugs & mucosal protectants

- 1.3.1 H₂-Receptor Antagonists
- 1.3.3 Chelates & Complexes
- 1.3.5 Proton Pump Inhibitors

1.4 Acute diarrhoea

1.4.2 Antimotility Drugs

1.5 Chronic bowel disorders

- 1.5.1 Aminosalicylates
- 1.5.2 Corticosteroids & Enemas
- 1.5.3 Drugs Affecting the Immune Response

Advanced therapies (biologic and targeted synthetic treatments)

1.6 Laxatives

- 1.6.1 Bulk-forming Laxatives
- 1.6.2 Stimulant Laxatives
- 1.6.3 Faecal Softeners
- 1.6.4 Osmotic Laxatives
- 1.6.5 Bowel Cleansing Preparation
- 1.6.6 Peripheral opioid-receptor antagonists
- 1.6.7 Other drugs used in constipation

1.7 Local preparations for anal & rectal disorders

- 1.7.2 Compound Haemorrhoidal Preparations with Corticosteroids
- 1.7.4 Management of anal fissures

1.9 Drugs affecting intestinal secretions

- 1.9.1 Drugs affecting biliary composition & flow
- 1.9.2 Bile acid sequestrants
- 1.9.4 Pancreatin

1.10 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

GASTRO / ENDOSCOPY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Faecal Incontinence (CG49)

Irritable Bowel Syndrome (CG61)

Diarrhoea and vomiting in children under 5 (CG84)

Constipation in children and young people (CG99)

Acute upper GI bleeding (CG141)

Dyspepsia and gastro-oesophageal reflux disease (CG184)

Coeliac disease: recognition, assessment and management (NG20)

Crohn's disease: management (NG129)
Ulcerative colitis: management (NG130)

Ulcerative colitis (acute exacerbations) - infliximab (TA163)

Crohn's disease - infliximab & adalimumab (TA187)

Constipation (women) - prucalopride (TA211)

Infliximab, adalimumab & golimumab for treating moderately to severely active ulcerative colitis (TA329)

Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

Naloxegol for treating opioid induced constipation (TA345)

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Obeticholic acid for treating primary biliary cholangitis (TA443)

Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Darvadstrocel for treating complex perianal fistulas in Crohn's disease (TA556)

Ustekinumab for treating moderately to severely active ulcerative colitis (TA633)

Naldemedine for treating opioid-induced constipation (TA651)

Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis (TA708)

Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

Teduglutide for treating short bowel syndrome (TA804)

Ozanimod for treating moderately to severely active ulcerative colitis (TA828)

Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)

Risankizumab for previously treated moderately to severely active Crohn's disease (TA888)

Upadacitinib for previously treated moderately to severely active Crohn's disease (TA905)

Mirikizumab for treating moderately to severely active ulcerative colitis (TA925)

Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over (TA956)

Risankizumab for treating moderately to severely active ulcerative colitis (TA998)

Elafibranor for previously treated primary biliary cholangitis (TA1016)


GMMMG Formulary


Formulary Homepage


Chapter 1: Gastro-Intestinal system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List











PbR X

infusion

enema

ICAM-1 Inhibitor
Alicaforsen


IBD as per NICE

RESTRICTEDGastro. Consultants only - pouchitis


blueteq


MMC BNF emc

PBRX NICE MMC BNF emc



1.6.7 Other drugs used in constipation		
Prucalopride		RESTRICTED - Adult women, Gastro.
SI		Consultants only
1mg; 2mg tablets	NICE MMC BNF emc	
Linaclotide		RESTRICTED - 3 rd line use Adults
31		Gastro. Consultants only
290 micrograms capsules	MMC BNF emco	





1.10 Miscellaneous preparations Glucarpidase RESTRICTED 2nd line rescue therapy Voraxaze ® 1,000 unit injection (see also sections 8.4, 10.4 & 13.14) PDRX MMC BNF @MC

,,			- · · · · · · · · · · · · · · · · · · ·
Non-Formulary Items			G⋈ <mark>M</mark> MG
Darvadstrocel (DNP)			REJECTED in line with
			NICE TA556
Alofisel® 5 million cells/mL injection Diarrhoea (adults)	NICE MMC	<u>emc</u> ⊕	Criterion 1
(DNP)			in line with GMMMG / NHSE
Dicycloverine hydrochloride (DNP)	ENNI		in line with GMMMG
	BN 6	emc _®	Criterion 2
Haemorrhoids (DNP)			in line with GMMMG / NHSE
Indigestion and heartburn (DNP)			in line with GMMMG / NHSE
Infant colic (DNP)			in line with GMMMG / NHSE
Infrequent constipation (duration less than 2 weeks) (DNP)			in line with GMMMG / NHSE
IQoro (DNP)			in line with GMMMG
Neuromuscular training device			Criterion 1
Lactase drops (DNP)			in line with GMMMG
e.g Colief®			Criterion 1
Lubiprostone			Discontinued Jan-19
capsules	NICE MMC	<u>emc⊚</u>	
Macrogols Klean-Prep® oral powder	MMC BNF	emco	Discontinued Apr-24
OTC haemorrhoid preparations (DNP)			in line with GMMMG
Power district.	NICE BNI	≥ emc⊚	
Racecadotril (DNP)			in line with GMMMG
capsules; granules for oral suspension; tablets		<u>emc</u> ⊚	Criterion 1
Rifaximin (DNP)	BNI		in line with GMMMG for Traveller's diarrhoea
200mg tablets (see also section 5.1.7)	NICE MMC BN	emc⊚	
Stoma deodorant sprays (DNP)			in line with GMMMG
			Criterion 3
VSL#3® / Vivomixx® food supplement (DNP)			in line with GMMMG
			Criterion 1

Section 2: Cardiovascular system

Supported by the formulary (click here)



2.1 Positive inotropic drugs

- 2.1.1 Cardiac Glycosides
- 2.1.2 Phosphodiesterase Inhibitors

2.2 Diuretics

- 2.2.1 Thiazides & Related Diuretics
- 2.2.2 Loop Diuretics
- 2.2.3 Potassium-sparing Diuretics & Aldosterone Antagonists
- 2.2.4 Potassium-sparing Diuretics with other Diuretics
- 2.2.5 Osmotic Diuretics

2.3 Anti-arrhythmic drugs

2.3.2 Drugs for Arrhythmias

2.4 Beta-adrenoceptor blocking drugs

2.5 Hypertension & heart failure

- 2.5.1 Vasodilator Antihypertensive Drugs
- 2.5.2 Centrally Acting Antihypertensive Drugs
- 2.5.4 Alpha-Adrenoceptor Blocking Drugs
- 2.5.5 Drugs Affecting the Renin-Angiotensin System
 - 2.5.5.1 Angiotensin-Converting Enzyme (ACE) Inhibitors
 - 2.5.5.2 Angiotensin-II Receptor Antagonists
 - 2.5.5.3 Renin Inhibitors
 - 2.5.5.4 Heart Failure

2.6 Nitrates, calcium-channel blockers & other antianginals

- 2.6.1 Nitrates
- 2.6.2 Calcium-channel Blockers
- 2.6.3 Other Antianginal Drugs
- 2.6.4 Peripheral Vasodilators & Related Drugs

2.7 Sympathomimetics

- 2.7.1 Inotropic Sympathomimetics
- 2.7.2 Vasoconstrictor Sympathomimetics
- 2.7.3 Cardiopulmonary Resuscitation

2.8 Anticoagulants & protamine

- 2.8.1 Parenteral Anticoagulants
- 2.8.2 Oral Anticoagulants
- 2.8.3 Protamine Sulfate

2.9 Antiplatelet drugs

2.10 Stable angina, acute coronary syndromes & fibrinolysis

2.10.2 Fibrinolytic Drugs

- 2.11 Antifibrinolytic drugs & haemostatics
- 2.12 Lipid-regulating drugs
- 2.13 Local sclerosants
- 2.14 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

CARDIOLOGY - medicine & prescribing policies / guidelines (MFT Policy Hub)

CARDIAC SURGERY - medicine & prescribing policies / guidelines (MFT Policy Hub)

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Familial hypercholesterolaemia (CG71)

Chest pain of recent onset (CG95)

Stable angina (CG126)

Lipid modification: CV risk assessment and the modification of blood lipids for the 1ry & 2ry prevention of CVD (CG181)

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

Chronic heart failure in adults: diagnosis and management (NG106)

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)

Hypertension in pregnancy: diagnosis and management (NG133)

Hypertension in adults: diagnosis and management (NG136)

Acute coronary syndromes (NG185)

Atrial fibrillation: diagnosis and management (NG196)

Volanesorsen for treating familial chylomicronaemia syndrome (HST13)

Acute coronary syndromes - glycoprotein Ilb/Illa inhibitors (review) (TA47)

Myocardial infarction - thrombolysis (TA52)

Guidance on the use of coronary artery stents (TA71) (partially updated by TA152)

Myocardial perfusion scintigraphy for the diagnosis and management of angina & MI (TA73) (partially updated bt TA95 & TA126)

Hypercholesterolaemia - Ezetimibe (TA132)

Coronary artery disease - drug eleuting stents (TA152)

Venous thromboembolism - dabigatran (TA157)

Rivaroxaban for the prevention of VTE (TA170)

Atrial Fibrillation - dronedarone (TA197)

Vascular disease - clopidogrel and dipyridamole (TA210)

Peripheral arterial disease - cilostazol, naftidrofuryl oxalate, pentoxifylline & inositol nicotinate (TA223)

Acute coronary syndromes - ticagrelor (TA236)

Venous thromboembolism - apixaban (hip and knee surgery) (TA245)

Atrial fibrillation - dabigatran etexilate (TA249)

Atrial fibrillation (stroke prevention) - rivaroxaban (TA256)

Venous thromboembolism (treatment & long term 2ry prevention) - rivaroxaban (TA261)

Stroke (acute, ischaemic) - alteplase (TA264)

Chronic heart failure - ivabradine (TA267)

Stroke & systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban (TA275)

Pulmonary embolism and recurrent venous thromboembolism - rivaroxaban (TA287)

Prasugrel with PCI for treating ACS (review of TA182) (TA317)

Dabigatran etexilate for the treatment and 2ry prevention of DVT and/or PE (TA327)

Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)

Apixaban for the treatment and 2ry prevention of DVT and/or PE (TA341)

Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

Edoxaban for preventing stroke and systemic embolism in people with non valvular atrial fibrillation (TA355)

Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (TA385)

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA394)

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)

Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA694)

Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)

Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)

Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders (TA748)

Empagliflozin for treating chronic heart failure with reduced ejection fraction (TA773)

Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides (TA805)

Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)

Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy (TA913)

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA929)

Tenecteplase for treating acute ischaemic stroke (TA990)

Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over (TA1051)


GMMMG Formulary


Formulary Homepage


Chapter 2: Cardiovascular system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List








2.4 Beta-adrenoceptor blocking drug	gs	Gм <mark>X</mark> мG
		NICE NG106
		NICE NG136
2.4 Beta-Adrenoceptor Blocking Drugs		NICE NG196
Atenolol		
GREEN	(S)(K(S)	
tablets; liquid; injection	BNF emco	
Bisoprolol fumarate		RESTRICTED adults.
GREEN		Cardiology Consultant only
tablets	MMC BNF emco	
Carvedilol		RESTRICTED adults.
GREEN	BWF	Cardiology Consultant only
tablets	MMC BNF emc	ALSO 2ND LINE FOR VARICEAL BLEED
Esmolol hydrochloride		RESTRICTED
	EW/III	I.V. only
njection	BNF emco	
Etilefrine hydrochloride		RESTRICTED Haematology
		Consultants - SCD
tablets	MMC	
Labetalol hydrochloride		RESTRICTED
GREEN	[B]W[=	oral preps in pregnancy
tablets; injection	BNF emco	
Metoprolol tartrate		
·	ENTE	
tablets; injection	BNF emco	
Nadolol	(RESTRICTED paeds. ventricular
		arrhythmias in long QT syndrome
tablets	MMC BNF emc	
Nebivolol		
tablets	BNF emc	
Propranolol hydrochloride	<u> </u>	RESTRICTED
GREEN	SWI	not in Cardiology
tablets; capsules; oral solution; injection	MMC BNF emc	-
Sotalol hydrochloride		
-		
tablets	BNF emco	




2mg; 4mg & 8mg tablets

MMC BNF emc


2.5.5.2 Angiotensin-II Receptor Antagonists		
MHRA Drug Safety Update (Feb-16): Spironolactone and renin-angiotensin system Candesartan cilexetil GREEN	stem drugs in heart failure: risk of potentially fatal hype	1 st line use hypertension
2mg; 4mg; 8mg; 16mg & 32mg tablets	MMC BNF emc	- V
Losartan potassium GREEN	DAILE.	2 nd line use hypertension
12.5mg; 25mg; 50mg & 100mg tablets	BNF emc	
Irbesartan GREEN		2nd line use hypertension
75mg;150mg & 300mg tablets	MMC BNF emc	
Valsartan		2 nd line use
GREEN		hypertension
40mg;80mg & 160mg capsules	MMC BNF emc	
Sacubitril / Valsartan	ENRIF.	RESTRICTED use in line with NICE TA388
24mg / 26mg; 49mg / 51mg & 97mg / 103mg tablets	NICE MMC BNF CMC	
2.5.5.3 Renin inhibitors		
Aliskiren (DNP)		RESTRICTED adults. Specialist initiation only
150mg; 300mg tablets	MMC BNF emc	
MHRA Drug Safety Update (Mar-12): Aliskiren (Rasilez ▼): risk of cardiovascul	ar and renal adverse reactions	
2.5.5.4 Heart Failure		
Dapagliflozin SA		RESTRICTED adults. Specialist initiation in line with TA679
Forxiga ® tablets	NICE MMC BNF CMC	
Empagliflozin SA		RESTRICTED adults. Specialist initiation in line with TA773
Jardiance ® tablets	NICE MMC BNF @mc@	




2.7 Sympathomimetics		GM <mark>₩</mark> MG
2.7.1 Inotropic Sympathomimetics		
Dobutamine		RESTRICTED I.V.
	(63)X)(A	Specialist use only
nfusion	BNF emco	
Oopamine hydrochloride		RESTRICTED /. V.
	I EXXIJE	Specialist use only
fusion	BNF emco	
Oopexamine		RESTRICTED 1. V.
		Specialist use only
fusion	BNF emco	
soprenaline		RESTRICTED I.V.
		Specialist use only
njection	BNF emco	
2.7.2 Vasoconstrictor Sympathomimetics		
Adrenaline acid tartrate O		Specialist use endoscopic sinus
	PANE	surgery
in 1000 (0.1%w/v) cutaneous solution)	MMC BNF emc	
Ephedrine hydrochloride		RESTRICTED 1. V.
	BINDE	Specialist use only
njection	BNF emc	
∕letaraminol [©]		
	BWIF	
njection	BNF emc	
Midodrine		Specialist use Cardiology /
SI		Healthcare of the elderly
ablets	MMC BNF emc	
loradrenaline acid tartrate		RESTRICTED 1. V.
	ENVE to delice	Specialist use only
nfusion	BNF emc	
Phenylephrine hydrochloride		RESTRICTED I.V.
		Specialist use only
njection	BNF emc	
2.7.3 Cardiopulmonary Resuscitation		
Adrenaline / Epinephrine		
- Side N	ESS VIP Now refusite year	
njection	BNF emc	





© Manchester University NHS Foundation Trust 2025






2.10 Stable angina, ACS & fibrinolysis		Gм <mark>Ж</mark> мG
Stable angina (BNF treatment summary)		
Acute coronary syndromes (BNF treatment summary)		
Fibrinolytic Drugs (BNF treatment summary)		NICE CG126
2.10.2 Fibrinolytic Drugs		NICE NG128
Tenecteplase RED		
injection	NICE MMC BNF EM	C ⊚
Streptokinase RED		
infusion	NICE BNF @M	IC (i)
Urokinase		
RED		
injection	BNF em	IC (i)
Alteplase		RESTRICTED
RED	Exp dilater	
injection; infusion	NICE MMC BNF em	IC⊕





Lipid-regulating drugs		
Alirocumab		RESTRICTED adults. Lipid Clinic
RED		Consultants in line with TA393
Praluent® injection	PBRX NICE MMC BNF @	emc⊛
Bempedoic acid (see also <i>Nustendi</i> ®) GREEN		RESTRICTED adults. Consultants in line with TA694
Nilemdo ® tablets	PBRX NICE MMC BNF @	emc⊛
Bempedoic acid with ezetimibe (see also Nilemdo®) GREEN		RESTRICTED adults. Consultants in line with TA694
Nustendi ® tablets	PBRX NICE MMC BNF @	emc
Evinacumab		RESTRICTED a dults. Consultants in
RED		ue <mark>teq line with TA1002</mark>
Repatha® injection	PBRX NICE MMC BNF @	mco
Evolocumab		RESTRICTED. Lipid Clinic
RED	BIME b	ueteq Consultants only for HoFH / & NICE
Repatha® injection	PBRX NICE MMC BNF @	mc TA394
Icosapent ethyl		RESTRICTED adults in line with NICE TA805
Vazkepa® capsules	PBRX NICE MMC BNF @	mc l
Inclisiran Green		RESTRICTED adults. Consultants in line with TA733
Leqvio® injection	PERX NICE MMC BNF @	for Primary Care Referral
Lomitapide		RESTRICTED adults. Lipid Clinic
RED EE	b	Ueteq Consultants in line with NHSE
Lojuxta® capsules	PBR X MMC BNF @	
Volanesorsen		RESTRICTED adults. Lipid Clinic
RED EE	bl	Ueteq Consultants in line with HST13
Waylivra® injection	PBRX NICE MMC BNF @	mc _®

2.13 Local sclerosants	G™MG
Local Scierosants	
Ethanolamine oleate	
RED	
injection	emc⊛
Sodium tetradecyl sulfate	
RED	
injection	emco



Non-Formulary Items	PBR X NICE	GMMG
Atorvastatin		in line with GMMMG
(DNP)	BNF	
30mg; 60mg tablets	PBR X NICE BNF emc	Criterion 2
Cilostazol (DNP)		REJECTED in line with NICE TA223
Pletal® 50mg; 100mg tablets	NICE MMC BNF emc	GMMMG Criterion 2
Diuretics with potassium (DNP)		in line with GMMMG
		Criterion 2
Doxazosin (DNP)		in line with GMMMG
M/R tablets / 8mg immediate release tablets	MMC BNF emc	Criterion 2
Inositol nicotinate (DNP)		REJECTED in line with NICE TA223
Hexopal® tablets	NICE MMC BNF (emco)	GMMMG Criterion 2
Moxisylyte (DNP)		in line with GMMMG
		Criterion 1
Pentoxifylline (DNP)		REJECTED in line with NICE TA223
Trental® tablets	NICE MMC BNF (emco)	GMMMG Criterion 2
Perindopril arginine (DNP)		in line with GMMMG
2.5mg; 5mg & 10mg tablets	NICE BNF @MC	Criterion 2
RESPeRATE (DNP)		in line with GMMMG
		Criterion 1
Simvastatin with ezetimibe (DNP)	BINE	in line with GMMMG
Inegy® 10mg/20mg; 10mg/40mg & 10mg/80mg tablets	NICE MMC BNF emco	Criterion 2

Section 3: Respiratory system

Supported by the formulary (click here)



3.1 Bronchodilators

- 3.1.1 Adrenoceptor Agonists
- 3.1.2 Antimuscarinic Bronchodilators
- 3.1.3 Theophylline
- 3.1.4 Compound Bronchodilator Preparations
- 3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers Inhaler Devices Nebuliser Diluent

3.2 Corticosteroids

Compound preparations

3.3 Cromoglicate & related therapy & leukotriene receptor antagonists

- 3.3.1 Cromoglicate & Related Therapy
- 3.3.2 Leukotriene Receptor Antagonists
- 3.3.3 Phosphodiesterase type-4 inhibitors

3.4 Antihistamines, hyposensitisation & allergic emergencies

- 3.4.1 Antihistamines
- 3.4.2 Allergen Immunotherapy
- 3.4.3 Allergic Emergencies

3.5 Respiratory stimulants & pulmonary surfactants

- 3.5.1 Respiratory Stimulants
- 3.5.2 Pulmonary Surfactants
- 3.6 Oxygen (refer to oxygen guidelines)
- 3.7 Mucolytics
- 3.8 Aromatic inhalations
- 3.9 Cough preparations
 - 3.9.1 Cough Suppressants

Cough Suppressants (Palliative Care ONLY)

- 3.9.2 Demulcent & expectorant cough preparations
- 3.10 Systemic Nasal Decongestants
- 3.11 Antifibrotics

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Idiopathic pulmonary fibrosis (CG163)

Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)

Asthma pathway (BTS, NICE, SIGN) (NG244)

Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

Venom anaphylaxis - immunotherapy pharmalgen (TA246)

Mannitol dry powder for inhalation for treating cystic fibrosis (TA266)

Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (review of TA133, TA201) (TA278)

Omalizumab for previously treated chronic spontaneous urticaria (TA339)

Roflumilast for treating chronic obstructive pulmonary disease (replaces TA244) (TA461)

Reslizumab for treating severe eosinophilic asthma (TA479)

Pirfenidone for treating idiopathic pulmonary fibrosis (replaces TA282) (TA504)

Benralizumab for treating severe eosinophilic asthma (TA565)

Lanadelumab for preventing recurrent attacks of hereditary angioedema (TA606)

Mepolizumab for treating severe eosinophilic asthma (replacing TA431) (TA671)

Berotralstat for preventing recurrent attacks of hereditary angioedema (TA738)

Dupilumab for treating severe asthma with type 2 inflammation (TA751)

Palforzia for treating peanut allergy in children and young people (TA769)

Tezepelumab for treating severe asthma (TA880)

lvacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)


GMMMG Formulary

Formulary Homepage


Chapter 3: Respiratory system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List





,,		. , ,
3.1.4 Compound Bronchodilator Preparations		GMMMG
Aclidinium bromide with formoterol fumarate dihydrate		3 rd line use
GREEN		COPD maintenance
Duaklir Genuair®	MMC BNF emc	
Glycopyrronium bromide with formoterol fumarate		3 rd line use
GREEN		COPD maintenance
Bevespi Aerosphere®	MMC BNF emc	
Glycopyrronium bromide with indacaterol maleate	1011010	3 rd line use
GREEN		COPD maintenance
Ultibro ®	MMC BNF emc	
Ipratropium bromide with salbutamol	MIMO BNP CITICS	
The contract with substitution		
Combivent®		
Tiotropium bromide monohydrate with olodaterol hydrochloride	BNF emc	3 rd line use
GREEN		COPD maintenance
October Description	2222	COFD maintenance
Spiolto Respimat® Umeclidinium bromide with vilanterol trifenatate	MMC BNF emc	a rd
GREEN Dromide with vilanterol trienatate		3 rd line use
		COPD maintenance
Anoro Ellipta®	MMC BNF emc	
3.1.5 Peak Flow Meters, Inhaler Devices & Nebulisers		GMMMG GMMMG GMMMG
Inhaler Devices		
Volumatic® (spacer inhaler)		
GREEN	ENF	
Large volume device with mouthpiece	NICE BNF emc	
Aerochamber® Plus (spacer device)		
GREEN	BNF	
Standard device with mouthpiece; Standard device with adult face mask	NICE	
Able Spacer® (spacer device)		
GREEN	188717	
	NICE MMC BNF	
Nebuliser Diluent	1011010	
Sodium chloride		
GREEN		
0.9% nebuliser diluent	DANK OMOG	
0.3 // Hebuliber Ulluetit	BNF emc	



MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration








MMC

300mg; 600mg tablets




3.6 Oxygen (refer to oxygen guidelines)










3.8 Aromatic inhalations	GM <mark>W</mark> MG
Aromatic Inhalations	
Benzoin Tincture, Compound, BP	
Friars' Balsam liquid	C ₀
Menthol and Eucalyptus Inhalation, BP 1980	
inhalation vapour BNF em	Co



3.10 Systemic nasal decongestants

Systemic Nasal Decongestants

NO DRUGS ARE RECOMMENDED FROM THIS GROUP




NHSE: OTC prescribing reduction

GMMMG

MHRA Drug Safety Update (Feb-24): Pseudoephedrine: risk of posterior reversible encephalopathy syndrome (PRES) & reversible cerebral vasoconstriction syndrome (RCVS)





Chapter 4: Central nervous system

Supported by the formulary (click here



- 4.1 Hypnotics & anxiolytics
 - 4.1.1 Hypnotics
 - 4.1.2 Anxiolytics
 - 4.1.3 Barbiturates
 - 4.1.4 Other hypnotics and anxiolytics
- 4.2 Drugs used in psychoses & related disorders
 - 4.2.1 Antipsychotic Drugs
 - 4.2.2 Antipsychotic Depot Injections
 - 4.2.3 Drugs used for mania and hypomania
- 4.3 Antidepressant drugs
 - 4.3.1 Tricyclic & Related Antidepressant Drugs
 - 4.3.2 Monoamine-Oxidase Inhibitors (MAOIs)
 - 4.3.3 Selective Serotonin Re-uptake Inhibitors (SSRIs)
 - 4.3.4 Other Antidepressant Drugs
- 4.4 CNS stimulants & drugs used for ADHD
- 4.5 Drugs used in the treatment of obesity
- 4.6 Drugs used in nausea & vertigo
- 4.7 Analgesics
 - 4.7.1 Non-Opioid Analgesics
 - 4.7.2 Opioid Analgesics
 - 4.7.3 Neuropathic Pain
 - 4.7.4 Antimigraine Drugs
- 4.8 Antiepileptic drugs
 - 4.8.1 Control of the Epilepsies
 - 4.8.2 Drugs Used in Status Epilepticus
- 4.9 Drugs used in Parkinsonism & related disorders
 - 4.9.1 Dopaminergic Drugs Used in Parkinsonism
 - 4.9.2 Antimuscarinic Drugs Used in Parkinsonism
 - 4.9.3 Drugs Used in Essential Tremor, Chorea, Tics & Related Disorders
- 4.10 Drugs used in substance dependence
- 4.11 Drugs for dementia
- Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Obsessive compulsive disorder (OCD) & body dismorphic disorder (BDD) (CG31)

Management of Obesity (CG43) (replaces TA22, TA31 & TA46)

Drug misuse: opioid detoxification (CG52)

Depression with a chronic physical health problem (CG91)

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)

Anxiety (CG113) (replaces CG22)

Neuropathic pain - pharmacological management (CG173)

Psychosis and schizophrenia in adults (CG178)

Bipolar disorder: the assessment and management in adults, children & young people in 1ry & 2ry care (CG185)

Narcolepsy with or without cataplexy in adults: pitolisant (ES8)

Eating Disorders: recognition and treatment (NG69)

Parkinsons's disease in adults (NG71)

Attention deficit hyperactivity disorder: diagnosis and management (NG87)

Stop smoking interventions and services (NG92)

Dementia: supporting people with dementia and their carers in health and social care (NG97)

Post-traumatic stress disorder (NG116)

Depression in children and young people: identification and management (NG134)

Epilepsies in children, young people and adults (NG217)
Depression in adults: treatment and management (NG222)

Motor Neurone Disease: Riluzole (TA20)

Guidance on the use of zaleplon, zolpidem & zopiclone for short-term management of insomnia (TA77)

Drug Misuse: Methadone & Buprenorphine (TA114)

Drug Misuse: Naltrexone (TA115) Smoking Cessation: Varenicline (TA123) Schizophrenia - aripiprazole (TA213)

Alzheimer's disease - donepezil, galantamine, rivastigmine & memantine (TA217) (replaces TA111)

Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

Bipolar disorder (children) - aripiprazole (TA292)

Nalmefene for reducing alcohol consumption in people with alcohol dependence (TA325)

Vortioxetine for treating major depressive episodes (TA367)

Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

Cannabidiol with clobazam for treating seizures associated with Dravet syndrome (TA614)

Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome (TA615)

Galcanezumab for preventing migraine (TA659)

Cenobamate for treating focal onset seizures in epilepsy (TA753)

Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy (TA758)

Fremanezumab for preventing migraine (replacing TA631) (TA764)

Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

Vutrisiran for treating hereditary transthyretin-related amyloidosis (TA868)

Eptinezumab for preventing migraine (TA871)

Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Rimegepant for preventing migraine (TA906)

Rimegepant for treating migraine (TA919)

Daridorexant for treating long-term insomnia (TA922)

Foslevodopa-foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

Atogepant for preventing migraine (TA973)

Tafamidis for treating transthyretin amyloidosis with cardiomyopathy (TA984)

Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)


Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over (TA1050)

GMMMG Formulary


Formulary Homepage

Chapter 4: Central nervous system


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




4.1.3 Barbiturates NO DRUGS ARE RECOMMENDED FROM THIS GROUP 4.1.4 Other hypnotics and anxiolytics Daridorexant hydrochloride GREEN Quviviq ® tablets RESTRICTED in line with NICE TA922 NOT for initiation in 2^{ry} care




4.2.3 Drugs used for mania and hypomania	
Lithium carbonate	PRESCRIBE BY BRAND NAME
AMBER RED	
4-1-4 M/D 4-1-1-4-	tor could not
tablets; M/R tablets	BNF emc®
Lithium citrate	PRESCRIBE BY BRAND NAME
AMBER RED	
	(CS) INITION (CS) (CS) (CS) (CS) (CS) (CS) (CS) (CS)
oral solution	BNF emc
Valproic acid	
SI	
	ESIN Establishment
Gastro-resistant tablets	BNF emc
MHRA Drug Safety Update (Apr-19): Valproate medicines and serious harms in pre-	gnancy: new Annual Risk Acknowledgement Form and clinical guidance
MUDA Drug Safaty Undata (May 10): Carbananama: concemitant use with valurais	acid not recommended



Escitalopram	RESTRICTED	
	Mental Health Trust initiation	on only
ablets	BNF emc	
IHRA Drug Safety Update (Dec-11): Citalopram and escitalopram: QT i	nterval prolongation	
3.4 Other Antidepressant Drugs		
/enlafaxine	RESTRICTED	
GREEN SI	initiation by Psychiatri	st
/I/R capsules; tablets; M/R tablets	MMC BNF emc	
/lirtazapine	RESTRICTED	
GREEN	initiation by Psychiatri	st
ablets; orodisperible tablets; oral solution	MMC BNF emco	
Duloxetine	RESTRICTED	
GREEN	initiation by Psychiatri	st
jastro-resistant tablets	BNF emc	
Flupentixol	RESTRICTED	
	initiation by Psychiatri	st
ablets	BNF emc	
Reboxetine	RESTRICTED	
	initiation by Psychiatri	st
ablets	MMC BNF emco	
	RESTRICTED	
	initiation by Psychiatri	st
apsules	BNF emc	
/ortioxetine	RESTRICTED	
GREY SA	initiation by Psychiatri	st
ablets	NICE MMC BNF CMC	





4.5 Drugs used in the treatment of obesity 4.5.1 Anti-Obesity Drugs Acting on the Gastro-Intestinal Tract Orlistat GREEN Consultant initiation - Paeds. only MHRA Drug Safety Update (Mar-14): Orlistat: theoretical interaction with antiretroviral HIV medicines



tablets

BNF emc





injection; rectal solution


Sulthiame U


Ospolot® 50mg tablets

Phenytoin sodium

capsules; oral suspension; injection

MFT Formulary V10.5 (May 2025)	Section 4		Central Nervous System
4.9 Drugs used in Parkinsonism	& related disord	ers	Gм <mark>₩</mark> мG
4.9.1 Dopaminergic Drugs Used in Parkinsonism			NICE NG71
Amantadine hydrochloride			RESTRICTED
SA			Specialist use only
apsules; oral solution	NICE	BNF emc®	
Apomorphine hydrochloride			RESTRICTED Specialist use only
njection; infusion	NICE MA	AC BNF emco	•
/IHRA Drug Safety Update (Apr-16): Apomorphine with domperidone: mi			
Cabergoline	3		RESTRICTED
SA			Specialist use only
ablets	NICE MA	C BNF emc	
Co-beneldopa			RESTRICTED
SA			Specialist use only
apsules; M/R capsules; dispersible tablets	NICE	BNF emc	
Co-careIdopa			RESTRICTED
SA (CANA)		BING- for children	Specialist use only
ablets; M/R tablets (DNP) intestinal gel	PbR X NICE	BNF emco	
Entacapone SA			RESTRICTED Specialist use only
ablets	NICE MA	AC BNF EMCO	• •
Foslevodopa with foscarbidopa		CIIIC	RESTRICTED
RED RED			Specialist use only
roduodopa ® 240mg/mL / 12mg/mL infusion	NICE MA	AC BNF emc	
Opicapone GREY SA			RESTRICTED 2 nd line
oraviles.	9.00	10 mag	Specialist use only
apsules		MC BNF emco	
Pramipexole SA			RESTRICTED 3 rd line add-on use Specialist use only
ablets; M/R tablets	MN	AC BNF emc	
Rasagiline SA			RESTRICTED patients with end of dose fluctuations
ablets	RATE.	AC BNF emco	
Ropinirole	0000	WO BINE CITICS	RESTRICTED
SA			Specialist use only
ablets; M/R tablets		BNF emc	
Rotigotine SA			RESTRICTED Specialist use only. NBM patients
canadarmal natabas	4405 440	10	appointed and only. Nom patients
ransdermal patches	NICE MI	MC BNF emco	DECTRICES.
Safinamide SA			RESTRICTED Specialist use only
ablets	MA	AC BNF emc	
Selegiline SA			RESTRICTED
			Specialist use only
sblets 1.9.2 Antimuscarinic Drugs Used in Parkinsonism		BNF emc	
Orphenadrine hydrochloride			
SI		BN F for children	
ral solution		BNF emc	
Procyclidine (Oral & IM) GREEN			
ablets; oral solution; injection		BNF emco	
Frihexyphenidyl hydrochloride			
ablet; syrup	MA	AC BNF emco	
	1000		





4.11 Drugs for dementia		GM <mark>M</mark> MG
4.11 Drugs for Dementia		NICE NG97
Donepezil hydrochloride		RESTRICTED Specialist use only
tablets; orodispersible tablets	NICE MMC BNF emc	
Galantamine		RESTRICTED Specialist use only
M/R capsules	NICE BNF emc	
MHRA Drug Safety Update (Dec-15): Letters sent to healthcare professionals		
Memantine hydrochloride		RESTRICTED Specialist use only
tablets; oral solution	NICE MMC BNF emc	
Rivastigmine GREEN		RESTRICTED Specialist use only
capsules; oral solution; transdermal patches	NICE MMC BNF @mc	

Will 11 Officially V10.5 (May 2025)	ection 4	Centi ai Nei Vous System
Non-Formulary Items		GM <mark>M</mark> MG
Aspirin and codeine		in line with CASSAGE
(DNP)		in line with GMMMG
Co-codaprin® tablets; dispersible tablets Cannabis-derived, cannabis-based and hemp products	BNF emco	Criterion 2
(DNP)		in line with GMMMG
with the exception of nabilone and <i>Epidyolex</i> ®		Criterion 1
Dextropropoxyphene with paracetamol		in line with GMMMG
(DNP)		
Co-proxamol® Dosulepin hydrochloride	NICE BNF EMC®	
(DNP)		in line with GMMMG
tablets; capsules	BNF emco	Criterion 1
Electromagnetic pulse therapy (DNP)		in line with GMMMG
ActiPatch®		Criterion 1
Eplontersen sodium		MFT not a commissioned centre
RED		patients referred to NAC - Royal Free
Wainzua ® 45mg/0.8mL injection	MMC BNF emco	
Eptinezumab RED (12)		
injection	MMC BNF emc	NOT STOCKED
Erenumab	INTUINI CITICO	
RED (E)		
injection Fractoming containing products	NICE MMC BNF emc	NOT STOCKED
Ergotamine-containing products (DNP)		in line with GMMMG
e.g. <i>Migril</i> ®		Criterion 1
Esketamine		in line with GMMMG
(DNP)		
Spravato ® nasal spray Fremanezumab	NICE MMC BNF emc	Criterion 1
RED (1)	blueteq	
injection	NICE MMC BNF emc	NOT STOCKED
Galcanezumab		
injection	MMC BNF emc	NOT STOCKED
Ganaxolone	MIMIC BNF CITICS	
		in line with NICE
Ztalmy® 50mg/mL oral suspension	NICE MMC emc®	
Haloperidol (DNP)	-NNW-	in line with GMMMG
500microgram tablets	NICE MMC BNF (emco)	Criterion 2
Infrequent migraine	initial State Cities	in line with GMMMG / NHSE
(DNP)		III IIIIe WILII GMMMG / NIISE
Levomepromazine		
(DNP)	BNE	in line with GMMMG
6mg tablets	BNF emco	
Loxapine (DNP)		in line with GMMMG
		Criterion 1
inhalation powder Meprobamate	BNF	
(DNP)		in line with GMMMG
tablets		Criterion 1
Meprobamate (DNP)		in line with GMMMG
tablets		Criterion 1
Mild toothache / teething		
(DNP)		in line with GMMMG / NHSE
e.g. paracetamol, ibuprofen, teething gels.		
Minor conditions associated with pain, discomfort and/or fever (DNP)		in line with GMMMG / NHSE
e.g. aches and sprains, headache, period pain, back pain		
, , , , , , , , , , , , , , , , , , , ,		

Nicotine (DNP)	in line with GMMMG
e-Voke®, Voke® (Nicotine inhaler)	Criterion 1
Oxycodone with naloxone	in line with GMMMG
(DNP)	
Targinact® M/R tablets MMC BNF @mco	Criterion 2
Paracetamol and tramadol (DNP)	in line with GMMMG
tablets; effervescent tablets	Criterion 2
Paracetamol mixture / mucilage	
(DNP)	in line with GMMMG
500mg / 5mL for topical use in patients with sore mouth or throat resulting from cancer treatment	Criterion 1
Paracetamol with buclizine and codeine (DNP)	in line with GMMMG
Migraleve ® (all presentations)	Criterion 1
Paracetamol with isometheptene	
(DNP)	in line with GMMMG
Midrid® 325mg / 65mg caspules	Criterion 1
Sufentanil citrate	in line with GMMMG
(DNP)	In line with GmmmG
Zalviso® 30microgram sublingual tablets	Criterion 2
Tafamidis	MFT not a commissioned centre
RED	patients referred to NAC - Royal Free
Vyndagel ® capsules NICE MMC BNF @MCO	
Travel sickness	in line with GMMMG / NHSE
(DNP)	III IIIIE WILII GMMMG / NFISE
Vutrisiran	MFT not a commissioned centre
	patients referred to NAC - Royal Free
Amvuttra ® injection NICE MMC BNF @MCC	

Section 5: Infections

Supported by the formulary (click here)



5.1 Antibacterial drugs

- 5.1.1 Penicillins
- 5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams
- 5.1.3 Tetracyclines
- 5.1.4 Aminoglycosides
- 5.1.5 Macrolides
- 5.1.6 Clindamycin
- 5.1.7 Some other Antibacterials
- 5.1.8 Sulfonamides & Trimethoprim
- 5.1.9 Antituberculosis Drugs
- 5.1.10 Antitleprotic Drugs
- 5.1.11 Metronidazole & Tinidazole
- 5.1.12 Quinolones
- 5.1.13 Urinary-tract Infections

5.2 Antifungal drugs

- 5.2.1 Triazole Antifungals
- 5.2.3 Polyene Antifungals
- 5.2.4 Echinocandin Antifungals
- 5.2.5 Other Antifungals

5.3 Antiviral drugs

- 5.3.1 HIV Infection
- 5.3.2 Herpesvirus Infection
- 5.3.3 Viral Hepatitis
- 5.3.4 Influenza
- 5.3.5 Respiratory Syncytial Virus (RSV)

5.4 Antiprotozoal drugs

- 5.4.1 Antimalarials
- 5.4.2 Amoebicides
- 5.4.3 Trichomonacides
- 5.4.4 Antigiardial drugs
- 5.4.5 Leishmaniacides
- 5.4.7 Drugs for toxoplasmosis
- 5.4.8 Drugs for pneumocystis pneumonia

5.5 Anthelmintics

- 5.5.1 Drugs for Threadworms (pinworms, Enterobius vermicularis)
- 5.5.2 Ascaricides
- 5.5.5 Schistosomicides (bilharziasis)
- 5.5.6 Filaricides

Non-Formulary Items

Trust Guidelines

MFT Adult Antimicrobial guidelines

MFT Paediatric Antimicrobial guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Prophylaxis against infective endocarditis (CG64)

Bacterial meningitis and meningococcal septicaemia (CG102)

Infection: Prevention & control of healthcare-associated infections in primary & community care (CG139)

Hepatitis B (Chronic) (CG165)

Tuberculosis (NG33)

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84) Otitis media (acute): antimicrobial prescribing (NG91)

Bronchiectasis (non-cystic fibrosis), acute exacerbation: antimicrobial prescribing (NG117)

Cough (acute): antimicrobial prescribing (NG120)

Surgical site infections: prevention and treatment (NG125)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Hepatitis B: Entecavir (TA153) Hepatitis B: Telbivudine (TA154)

Oseltamivir, Amantadine & Zanamivir for prophylaxis of Influenza (TA158)

Oseltamivir, Amantadine & Zanamivir for treatment of Influenza (TA168)

Hepatitis B: Tenofovir disoproxil (TA173)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Sofosbuvir for treating chronic hepatitis C (TA330)

Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)

Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Elbasvir-grazoprevir for treating chronic hepatitis C (TA413)

Sofosbuvir-velpatasvir for treating chronic hepatitis C (TA430)

Glecaprevir-pibrentasvir for treating chronic hepatitis C (TA499)

Sofosbuvir-velpatasvir-voxilaprevir for treating chronic hepatitis C (TA507)

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Cabotegravir with rilpivirine for treating HIV-1 (TA757)

Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

Bulevirtide for treating chronic hepatitis D (TA896)

Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

Molnupiravir for treating COVID-19 (TA1056)

GMMMG Formulary

Formulary Homepage

Chapter 5: Infections

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

RESTRICTED USE ANTIBIOTICS

- 1. Must be recommended / approved for use by consultant medical microbiologist
- 2. The name of the microbiologist must be documented on the prescription chart. The indication must be documented.
- 3. Only available from Pharmacy

RESERVED USE ANTIBIOTICS

RESERVED USE ANTIBIOTICS			
1. Can be used only in accordance with t	he restrictions outlined b	elow.	
2. Indication must be clearly documented	d on the prescription char	t.	
3. If being used outside of guidelines Mic	robiology approval must l	be sought as above.	
UNRESTRICTED USE ANTIBIOTICS			
1. Can be used according to MFT Trust g	uidelines, (those drugs no	ot marked Restricted or Reserv	ed)
5.1 Antibacterial drugs	GMMG Greeter Manchester Letter in Respond Com-		GM <mark>M</mark> MG
5.1.1 Penicillins			
5.1.1.1 Benzylpenicillin & Phenoxymethyl	penicillin		
Benzylpenicillin sodium (Penicillin G)			
		司以图	
600mg injection		BNF emco	
Phenoxymethylpenicillin (Penicillin V)			
		티커/티	
tablets		BNF emco	
Benzathine benzylpenicillin 0		SASHI.	RESTRICTED
		BINIF	unlicensed treatment for syphilis
injection		BNF emco	
5.1.1.2 Penicillinase-Resistant Penicillins			
Flucloxacillin			
		司列恩	
capsules; injection; oral solution		MMC BNF emc	
Temocillin			RESTRICTED infection caused by
			multi-resistant coliforms.
1g injection		MMC BNF emc	Micro only
5.1.1.3 Broad Spectrum Penicillins			
Amoxicillin			
		Est Niller	
capsules; oral suspension; injection		BNF emc	
Co-amoxiclav			
		Est Niller	
tablets; oral suspension; injection		BNF emc	
5.1.1.4 Antipseudomonal Penicillins			
Piperacillin with tazobactam			RESERVED
			serious / resistant infections
injection		MMC BNF emc	
Ticarcillin with clavulanic acid			RESERVED


	SNIP Granden	
tablets; oral suspension; injection	BNF emc	
5.1.1.4 Antipseudomonal Penicillins		
Piperacillin with tazobactam	RESERVED	Т
	serious / resistant infections	
injection	MMC BNF emc	
Ticarcillin with clavulanic acid	RESERVED	
	serious / resistant infections	
Timentin® 3.2g injection	MMC BNF emc	
5.1.1.5 Mecillinams		
Pivmecillinam hydrochloride	RESTRICTED UTIs caused by	
	resistant coliforms	


	ES RICE for children	resistant coliforms
200mg tablets	MMC BNF emc	
5.1.2 Cephalosporins, Carbapenems & other Beta-Lactams		BNF BNF BNF
5.1.2.1 Cephalosporins		
Cefalexin		

Cefalexin	
	ENNIF
caspules; tablets; oral suspension	BNF emc
Cefazolin	RESTRICTED
injection MN	MC BNF emc on Micro. advice only
Cefotaxime	RESERVED
	as per guidelines for children
injection	BNF emco
Ceftriaxone	RESERVED
	as per guidelines for children
injection	BNF emc

injection	BNF emc®	
Ceftriaxone	RESERVED	
	as per guidelines for children	
injection	BNF emc	
Cefuroxime	RESERVED	
	as per guidelines for children	
injection	BNF emc	

Cefixime		RESERVED
		GU infections only
tablets	MANAO (TANE) (AMAO)	
Ceftazidime	MMC BNF emc	
Certaziumie		RESERVED
	ENTE For children	pseudomonas infection in CF
injection	MMC BNF emc	
Cetazidime with avibactam		RESERVED for
		gram negative organisms
Zavicefta ® infusion	MMC BNF emc	Micro. Consultant only
Ceftolozane sulfate with tazobactam sodium		RESERVED for
		gram negative organisms
Zerbaxa® infusion	MMC BNF emc	Micro. Consultant only
Ceftaroline fosamil	1011010	RESERVED
Contaionino rosumi		
	SIMF for children	CAP & cSSTI treatment.
Zinforo® infusion	MMC BNF emc	Micro. Consultant only
Cefoxitin		RESERVED for treatment of
	SING for children	mycobacterium abscessus in CF.
injection	MMC BNF emc	Micro. Consultant only
Cefiderocol	<u></u>	RESERVED for
- · · · · · · ·		gram negative organisms
Fetcroja® infusion	MMC BNF emc	Micro. Consultant only
5.1.2.2 Carbapenems		
Ertapenem		RESTRICTED
	8-00 NOVE (18-00)	Outpatient therapy only
	EN NIF	Catpationt thorapy only
infusion	MMC BNF emc	
Imipenem with cilastatin		RESTRICTED
		Non-Tuberculous Mycobacteria in CF
infusion	MMC BNF emc	
Imipenem with cilastatin & relebactam	WIW BIT	
miliperiem with chastatin & relebactain		RESTRICTED
Recarbrio ® infusion	MMC BNF emc	Micro. Consultant only
Meropenem		RESERVED
·	(m2) & (f) = 1	as per guidelines
	(LES) (N) (F for children	do por gardonneo
injection	MMC BNF emc	
Meropenem with vaboractam		RESTRICTED
		RESTRICTED
Vaborem® infusion	MMC BNF emco	Micro. Consultant only
5.1.2.3 Other Beta-Lactam antibiotics	WIWIO BINE CITICS	
A 4		
Aztreonam		RESTRICTED
	(23 M) (2)	gram negative organisms
injection	BNF emco	
Aztreonam lysine	<u> </u>	RESTRICTED 3 rd line CF patients with
RED (££)		
	ESIXUE for children	chronic pulmonary infection
Cayston® nebuliser solution	MMC BNF emc	
Aztreonam with avibactam sodium		
Emblaveo® infusion	AAAAA	
	MMC BNF emc⊚	
5.1.3 Tetracyclines		
Doxycycline		
capsules; tablets; dispersible tablets	MMC BNF emc	
	www BNF CITCO	
Oxytetracycline		
	ENNE Sou administration	
tablets	BNF emco	
Demeclocycline hydrochloride		RESTRICTED
• • • • • • • • • • • • • • • • • • • •	Ben DADAN Hamil	SIADH only
	COLINATE Constitution	JIADIT OTHY
capsules (see also section 6.5.2)	MMC BNF emc	
Lymecycline		RESTRICTED
		Non-Formulary
408mg capsules (see also section 13.6.2)	MMC BNF emc	MMC approved for GP referral
Minocycline	WIW CITCO	approved for or referred
miniocycline		
	ESTNITT Grant and selections	
capsules; tablets	MMC BNF emc	
Tigecycline		RESERVED
 	##9700Xf0###	as per guidelines
	EN III	
infusion	MMC BNF emc	





Ofloxacin

RESTRICTED
GU infections only

tablets (see also section 11.3.1)

MHRA Drug Safety Update (Jan-24): Fluoroquinolone antibiotics: must now only be prescribed when other commonly recommended antibiotics are inappropriate

MHRA Drug Safety Update (Sep-23): Fluoroquinolone antibiotics: suicidal thoughts and behaviour

BNF emc

MHRA Drug Safety Update (Dec-20): Systemic & inhaled fluoroquinolones: small risk of heart valve regurgitation; consider other therapeutic options first in patients at risk


MHRA Drug Safety Update (Aug-23): Fluoroquinolone antibiotics: reminder of the risk of disabling and potentially long-lasting or irreversible side effects


MHPA Drug Safaty Lindate (Jul 20): Systemically administered WGE nathyray inhibitors: risk of analyses and artary discarding


MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection


tablets


MHRA Drug Safety Update (Mar-19): Fluoroquinolones: new restrictions / precautions for use due to reports of disabling & potentially long-lasting or irreversible side effects MHRA Drug Safety Update (Nov-18): Systemic & inhaled fluoroquinolones: small increased risk of aortic aneurysm & dissection; advice for prescribing in high-risk patients















5.4.5 Leishmaniacides		
Meglumine antimoniate	RESTRICTED	
RED	treatment of Leishmaniacides	S
injection	MMC BNF emc	
Paromomycin U	RESTRICTED	
RED	treatment of Crypotosporidios	sis
tablets	MMC BNF emc	
Sodium stibogluconate		
RED	RESTRICTED	
	treatment of Leishmaniacides	S
injection	MMC BNF emc	
5.4.7 Drugs for toxoplasmosis		
Sulfadiazine 0	RESTRICTED	
RED	treatment of toxoplasmosis	
tablets	BNF emc micro. recommendation only	У
5.4.8 Drugs for pneumocystis pneumonia		
Atovaquone U	RESTRICTED	
RED	Specialist use only	
oral suspension	BNF emc	
Pentamidine isethionate U	RESTRICTED	
RED	Specialist use only	
	Specialist use only	
injection	BNF emc	



Section 6: Endocrine system

Supported by the formulary (click here)



6.1 Drugs used in diabetes

6.1.1 Insulins

6.1.1.1 Short-acting insulins

6.1.1.2 Intermediate & long-acting insulins

Biphasic insulins

6.1.2 Antidiabetic drugs

6.1.2.1 Sulphonylureas

6.1.2.2 Biguanides

6.1.2.3 Other antidiabetic drugs

Alpha alucosidase inhibitors

Dipeptidyl peptidase-4 (DPP-4) inhibitors

Rapid acting insulin secretagogues (meglitinides)

Glucagon-like peptide-1 (GLP-1) receptor agonists

Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Thiazolidinediones

6.1.4 Treatment of hypoglycaemia

6.1.5 Treatment of diabetic nephropathy and neuropathy

6.1.6 Diagnostic and monitoring agents for diabetes mellitus

6.2 Thyroid & antithyroid drugs

6.2.1 Thyroid hormones

6.2.2 Antithyroid drugs

6.3 Corticosteroids

6.3.1 Replacement therapy

6.3.2 Glucocorticoid therapy

6.4 Sex hormones

6.4.1 Female sex hormones and their modulators

6.4.1.1 Oestrogens & HRT

6.4.1.2 Progestogens and progesterone receptor modulators

6.4.2 Male sex hormones & antagonists

6.5 Hypothalamic and pituitary hormones & anti-oestrogens

6.5.1 Hypothalamic & anterior pituitary hormones & anti-oestrogens

6.5.2 Posterior pituitary hormones & antagonists

6.6 Drugs affecting bone metabolism

6.6.1 Calcitonin & parathyroid hormone

6.6.2 Bisphosphonates & other drugs affecting bone metabolism

6.7 Other endocrine drugs

6.7.1 Bromocriptine & other dopaminergic drugs

6.7.2 Drugs affecting gonadotrophins

6.7.3 Metyrapone

6.7.4 Somatomedins

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Safer insulin prescribing (KTT20)

Diabetes in pregnancy: management from preconception to the postnatal period (NG3)

Type 1 diabetes in adults: diagnosis and management (NG17)

Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NG18)

Diabetic foot problems: prevention and management (NG19)

Type 2 diabetes in adults: management (NG28)

Heavy menstrual bleeding: assessment and management (NG88)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Human growth hormone - adults (TA64)

Diabetes (type 1) - insulin pump therapy (TA151)

Osteoporosis - Primary Prevention (TA160)

Osteoporosis - Secondary Prevention (TA161)

Human growth hormone (somatropin) for the treatment of growth failure in children (review) (TA188)

Osteoporotic Fractures - denosumab (TA204)

Bone metastases from solid tumours - denosumab (TA265)

Type 2 diabetes - Dapagliflozin combination therapy (TA288)

Diabetes (type 2) - canagliflozin (TA315)

Tolvaptan for treating autosomal dominant polycystic kidney disease (TA358)

Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)

Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)

Bisphosphonates for treating osteoporosis (TA464)

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (TA572)

Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes (TA583)

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Sotagliflozin with insulin for treating type 1 diabetes (TA622)

Liraglutide for managing overweight and obesity (TA664)

Dapagliflozin for treating chronic kidney disease (TA775)

Romosozumab for treating severe osteoporosis (TA791)

Relugolix-estradiol-norethisterone acetate for treating moderate to severe symptoms of uterine fibroids (TA832)

Somatrogon for treating growth disturbance in people 3 years and over (TA863)

Tirzepatide for treating type 2 diabetes (TA924)

Empagliflozin for treating chronic kidney disease (TA942)

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)

Abaloparatide for treating osteoporosis after menopause (TA991)

Burosumab for treating X-linked hypophosphataemia in adults (TA993)

Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

Tirzepatide for managing overweight and obesity (TA1026)


GMMMG Formulary

Formulary Homepage

Chapter 6: Endocrine system

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



MHRA Drug Safety Update (Nov-23): Ozempic ▼ (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products

MMC BNF emc

NICE MMC BNF emc

NICE MMC BNF emc

Ozempic ® injection

Semaglutide

Rybelsus® tablets

Mounjaro ® injection

Tirzepatide

GREEN


GREEN

RESTRICTED

as per by $\operatorname{\mathsf{GMMMG}}$


RESTRICTED

as per NICE / GMMMG T2DM pathway see also Non-formulary section





MHRA Drug Safety Update (Oct-24): Insulin pumps & CGM equipment: guidance for users on reporting suspected adverse incidents & safety concerns to the MHRA's Yellow Card






MFT Formulary v10.5 (May 2025)	Section 6	Endocrine System
6.4 Sex hormones		G∞MMG
4.1 Female sex hormones and their modulators		
4.1.1 Oestrogens & HRT		
onjugated oestrogens with progestogen		
remique $f (Conjugated oestrogens with medroxyprogesterone)$		2 nd line use oral
GREEN		(continuous combined HRT)
blets	BNF emc	
stradiol with Progestogen		
Elleste-Duet® (Estradiol with norethisterone)		1 st line use oral
		(sequential HRT)
ablets	BNF emc	and
Femoston® (Estradiol with dydrogesterone)		2 nd line use oral
		(sequential HRT)
Aliovance® (Estradiol with norethisterone)	BNF emc	4 St
GREEN (ESTIBUTION WITH HOTEURISTERORE)		1 st line use oral (continuous combined HRT)
	94940	(continuous combined HRT)
Evorel Conti® (Estradiol with norethisterone)	MMC BNF emc	RESTRICTED
GREEN (LISTINGION WITH HOTELHISTERONE)		(Continuous combined HRT)
		when oral contraindicated
atch	MMC BNF emc	
Evorel Sequi® (Estradiol with norethisterone)		RESTRICTED
GREEN		Paed. Endocrine Consultants
atch	MMC BNF emc	
Estradiol only		
Elleste Solo®		1 st line use oral
GREEN		(oestrogen only HRT)
ablets	BNF emc	
estradot ®		RESTRICTED
GREEN		(Oestrogen only HRT)
atch	CANE AMAR	when oral contraindicated.
Evorel®	BNF emc	RESTRICTED
GREEN		Paed. Endocrine Consultants
atch	MMC	raed. Endocrine Consultants
Ethinylestradiol, raloxifene & tibolone	MMC BNF emc	
Ethinylestradiol		2 microgram tablets (unlicensed
GREEN	ENNE	for amenorrhoea
ablets	MMC BNF emc	
Raloxifene hydrochloride	William Cinica	RESTRICTED
SA		Specialist Med. Consultant only
ablets	NICE MMC BNF emc	NICE TA160 / TA161
libolone libolone		3 rd line use oral
GREEN		(continuous combined HRT)
ablets	BNF emc	
6.4.1.2 Progestogens and progesterone receptor modulators	BNP	
6.4.1.2 Progestogens and progesterone receptor modulators Dydrogesterone	BN CIRC	
	BNF GIRES	
	emco	
Dydrogesterone ablets Medroxyprogesterone acetate		
Dydrogesterone ablets		
Dydrogesterone ablets Medroxyprogesterone acetate		
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection Medroxyprogesterone acetate	emc⊚	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection	emc⊚	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection Medroxyprogesterone acetate	emc⊚	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Sayana Press ® 104mg/0.65 mL injection Norethisterone	emc®	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera® 150mg/mL injection Medroxyprogesterone acetate GREEN	emc®	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Sayana Press ® 104mg/0.65 mL injection Norethisterone	emc®	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Oepo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Gayana Press ® 104mg/0.65 mL injection Norethisterone GREEN ablets Progesterone	emco BNF emco	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Oepo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Gayana Press ® 104mg/0.65 mL injection Norethisterone GREEN ablets Progesterone	emco BNF emco	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Oepo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Gayana Press ® 104mg/0.65 mL injection Norethisterone GREEN ablets Progesterone	emco BNF emco	
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Dayana Press ® 104mg/0.65 mL injection Norethisterone GREEN ablets Progesterone GREEN Display a Red GREEN Display acetate GREEN Display acetate GREEN Display acetate GREEN Display acetate	BNF emco	RESTRICTED
Ablets Medroxyprogesterone acetate GREEN Depo-Provera® 150mg/mL injection Medroxyprogesterone acetate GREEN Depo-Provera® 150mg/mL injection Medroxyprogesterone acetate GREEN Depo-Provera® 150mg/mL injection Morethisterone GREEN Depo-Provera® 150mg/mL injection	BNF emco	RESTRICTED Specialist use only uterine fibroid
Oydrogesterone ablets Medroxyprogesterone acetate GREEN Depo-Provera ® 150mg/mL injection Medroxyprogesterone acetate GREEN Dayana Press ® 104mg/0.65 mL injection Norethisterone GREEN ablets Progesterone GREEN Display a Red GREEN Display acetate GREEN Display acetate GREEN Display acetate GREEN Display acetate	BNF emco	








Evenity ® injection

NICE MMC BNF emc



MHRA Drug Safety Update (Jan-20): Mecasermin (Increlex ▼): risk of benign and malignant neoplasia

MF1 Formulary V10.5 (May 2025)	Section 6	Endocrine System
Non-Formulary Items		GM <mark>₩</mark> MG
Carbimazole (DNP)		in line with GMMMG
10mg; 15mg tablets	MMC BNF emc	
Chlorpropamide (DNP)		in line with GMMMG
ablets	BNF	Criterion 1
Fezolinetant		
Veoza® 45mg tablets	BNF emco	
MHRA Drug Safety Update (Apr-25): Fezolinetant ▼ (Veoza): risk of liver injury	; new recommendations to minimise risk	
Gliclazide (DNP)		in line with GMMMG
Modified-release tablets (e.g. Diamicron® MR)	BNF emco	Criterion 2
Hypurin® Bovine Isophane		Discontinued July 2017
Isophane insulin	emco	
Hypurin® Bovine Lente		Discontinued July 2017
Insulin zinc suspension	emco	
Hypurin® Bovine Neutral		Discontinued July 2017
Insulin bovine	NICE @MC®	
Liraglutide RED		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Saxenda® 6mg/mL pre-filled pen	NICE MMC BNF (emc)	
Lixisenatide		Discontinued June 2022 / December 2023
Lyxumia® 10 microgram; 20microgram injection	MMC BNF emc	
Metformin hydrochloride (DNP)		in line with GMMMG
1g immediate-release tablets	BNF emco	Criterion 2
Nateglinide		Discontinued August 2020
tablets	MMC BNF emc	
Pen needles 8mm, 10mm, or 12mm in length (DNP)		in line with GMMMG
		Criterion 1
Pen needles costing in excess of £5 per 100 (DNP)		in line with GMMMG
0		Criterion 3
Semaglutide RED		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Wegovy® injection	NICE MMC BNF emc	
Sotagliflozin		Withdrawn August 2022
Zynquista ® 200mg tablets	NICE MMC emc®	
Tirzepatide (DNP)		Weight loss - MFT is not a commissioned weight management service. Not for initiation, only for patients initiated at NCA.
Mauriara ® injection	NICE ARRAO DALE OMO	
Mounjaro ® injection	NICE MMC BNF EMC®	

Section 7

Section 7: Obstetrics, gynaecology & urinary tract disorders



7.1 Drugs used in Obstetrics

7.1.1 Prostaglandins & oxytocics

7.1.1.1 Drugs affecting the ductus arteriosus

7.1.2 Mifepristone

7.1.3 Myometrial relaxants

7.2 Treatment of vaginal & vulval conditions

7.2.1 Preparations for vaginal & vulval changes

7.2.2 Vaginal & vulval infections

7.3 Contraceptives

7.3.1 Combined hormonal contraceptives

Ethinylestradiol with Desogestrel

Ethinylestradiol with Gestodene

Ethinylestradiol with Levonorgestrel

Ethinylestradiol with Norelgestromin

Ethinylestradiol with Norethisterone Ethinylestradiol with Norgestimate

Mestranol with Norethisterone

7.3.2 Progestogen-only contraceptives

7.3.2.1 Oral progestogen-only contraceptives

7.3.2.2 Parenteral progestogen-only contraceptives

7.3.2.3 Intra-uterine progestogen-only device

7.3.5 Emergency contraception

7.4 Drugs for genito-urinary disorders

7.4.1 Drugs for urinary retention

7.4.2 Drugs for urinary, enuresis & incontinence

7.4.3 Drugs used in urological pain

7.4.4 Bladder instillations & urological surgery

7.4.5 Drugs for erectile dysfunction

7.4.6 Drugs for premature ejaculation

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Long-acting reversible contraception (CG30)

Lower urinary tract symptoms (CG97)

Nocturnal enuresis - the management of bedwetting in children and young people (CG111)

Antenatal and postnatal mental health: clinical management and service guidance (CG192)

Heavy menstrual bleeding: assessment and management (NG88)

Urinary incontinence and pelvic organ prolapse in women: management (NG123)

Caesarean birth (NG192)

Antenatal care for uncomplicated pregnancies (NG201)

Inducing labour (NG207)

Intrapartum care for healthy women and babies (NG235)

Overactive bladder - mirabegron (TA290)

Pentosan polysulfate sodium for treating bladder pain syndrome (TA610)

Vibegron for treating symptoms of overactive bladder syndrome (TA999)


GMMMG Formulary

Formulary Homepage


Chapter 7: Obstetrics, gynaecology & urinary tract disorders


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List




MHRA Drug Safety Update (Apr-25): Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma









7.4.4 Bladder instillations & urological surgery			
Chlorhexidine			
RED	EIRIF for attrictive		
0.02% irrigation solution	BNF	emc⊚	
Dimethyl sulfoxide U			
50% solution		emc⊕	
Glycine			
1.5% irrigation solution	BNF	emc⊛	
Sodium chloride			
RED	(B) X][F		
0.9% irrigation solution	BNF	emc⊛	
Sodium citrate			
KED	BNF for children		
3% irrigation solution	BNF	emc⊕	
Sodium hyaluronate			RESTRICTED
			Urology Consultants only
Cystistat® 40mg/50mL bladder instillation	MMC	emc⊕	
Sodium hyaluronate with sodium chondroitin sulfate			RESTRICTED
			Urology Consultants only
iAluRil® 800mg/50mL (1.6% w/v) / 1g/50mL (2% w/v) bladder instillation 7.4.5 Drugs for erectile dysfunction	MMC	emc⊚	
Alprostadil			DESTRICTED
GREEN	(=1000)		RESTRICTED Urology Consultants only
aroam; injection; urathral eticke	ISIN.IF to rehitdrer	ama a	Grology Consultants only
cream; injection; urethral sticks Aviptadil with phentolamine mesilate	MMC BNF	emc	RESTRICTED
SI SI			Urology Consultants only
Invicorp ® injection	MMC BNF	@mc@	c. c.egy concurrence cm,
Sildenafil		CITIC	RESTRICTED
GREEN OF RED PAH			1 ^{RY} Care referral only
injection; oral suspension; tablets (see also section 2.5.1)	MMC BNF	emc@	•
MHRA Drug Safety Update (Nov-18): Sildenafil (Revatio & Viagra): reports of PPHN following in-utero			auterine growth restriction
Tadalafil			RESTRICTED
GREEN OF RED PAH			1 ^{RY} Care referral only
tablets (see also section 2.5.1)	MMC BNF	emc⊚	
Vardenafil			RESTRICTED
			1 ^{RY} Care referral only
tablets	MMC BNF	emc⊕	
7.4.6 Drugs for premature ejaculation (DNP)			
NOT STOCKED			

Non-Formulary Items		Gм <mark>™</mark> мG
Dapoxetine hydrochloride (DNP)		in line with GMMMG
Priligy® 30mg; 60mg tablets	BNF emco	Criterion 1
Doxazosin (DNP)	SNI SNI	in line with GMMMG
img M/R tablets; 8mg tablets	BNF emco	Criterion 2
Licensed and off-label topical anaesthetics (DNP)		in line with GMMMG
		Criterion 1
lild cystitis (2-3 days)		in line with GMMMG / NHSE
g. Potassium citrate mixture or sachets, cranberry products		
Tadalafil (DNP)		in line with GMMMG
2.5mg tablets	BNF emco	Criterion 2
Tamsulosin with dutasteride		in line with GMMMG
400microgram / 500microgram hard capsules	BNF emc	Criterion 1

Section 8: Malignant disease & immunosuppression

Supported by the formulary (click here)



8.1 Cytotoxic drugs

Drugs for cytotoxic-induced side-effects

- 8.1.1 Alkylating drugs
- 8.1.2 Anthracyclines & other cytotoxic antibiotics
- 8.1.3 Antimetabolites
- 8.1.4 Vinca alkaloids & etoposide
- 8.1.5 Other antineoplastic drugs

8.2 Drugs affecting the immune response

- 8.2.1 Antiproliferative immunosuppressants
- 8.2.2 Corticosteroids & other immunosuppressants
- 8.2.3 Anti-lymphocyte monoclonal antibodies
- 8.2.4 Other immunomodulating drugs

8.3 Sex hormones & hormone antagonists in malignant disease

- 8.3.1 Oestrogens
- 8.3.2 Progestogens
- 8.3.3 Androgens
- 8.3.4 Hormone Antagonists
 - 8.3.4.1 Breast Cancer
 - 8.3.4.2 Gonadorelin analogues & gonadotrophin-releasing hormone antagonists
 - 8.3.4.3 Somatostatin analogues

8.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

NICE Guidance

Advanced breast cancer (CG81)

Familial breast cancer (CG164)

Hepatitis B (chronic) (CG165)

Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

Selumetinib for treating symptomatic & inoperable plexiform neurofibromas associated with type 1 neurofibromatosis (HST20)

Early and locally advanced breast cancer: diagnosis and management (NG101)

Lung cancer: diagnosis and management (NG122)

Prostate cancer: diagnosis and management (NG131)

Colorectal cancer (NG151)

Temozolomide for malignant glioma (TA23)

Leukaemia (lymphocytic) - fludarabine (TA29)

Trastuzumab for advanced breast cancer (TA34)

Paclitaxel for ovarian cancer (TA55)

Capecitabine and Tegafur Uracil for Colorectal Cancer (TA61)

Imatinib for chronic myeloid leukaemia (TA70) (partially updated by TA425 & TA426)

Hepatitis C: Chronic (TA75) (extended by TA106 - partially updated by TA200 & TA300)

Gastrointestinal stromal tumours - imatinib (TA86) (partially updated by TA209)

Hepatitis B: Chronic (TA96) (partially updated by CG165)

Colon cancer (adjuvant) - capecitabine and oxaliplatin (TA100)

Docetaxel for prostate cancer (hormone-refractory) (TA101)

Hepatitis C: Peginterferon & Ribavirin (TA106) (partially updated by TA200 & TA300)

Paclitaxel for early breast cancer (TA108)

Docetaxel for early breast cancer (TA109)

Gemcitabine for Breast Cancer (TA116)

Bevacizumab & Cetuximab in metastatic colorectal cancer (TA118) (partially updated by TA242)

Leukaemia (lymphocytic) - fludarabine (TA119)

Carmustine implants and temozolomide for gliomo (newly diagnosed & high grade) (TA121)

Pemetrexed for lung cancer (non small cell) (TA124)

Multiple sclerosis - natalizumab (TA127)

Bortezomib for relapsed multiple myeloma (TA129)

Pemetrexed for mesothelioma (TA135)

Rituximab for follicular non-Hodgkin's lymphoma (TA137)

Head and neck cancer - cetuximab (TA145)

Renal cell carcinoma - sunitinib (TA169)

Lenalidomide - multiple myeloma (TA171)

Rituximab for the first-line treatment of chronic lymphocytic leukaemia (TA174)

Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

Renal Cell Carcinoma (TA178)

Sunitinib for gastrointestinal stromal tumours (TA179)

Pemetrexed for lung cancer (non-small cell) - first line treatment (TA181)

Cervical cancer (recurrent) - topotecan (TA183)

Lung cancer (small cell) - topotecan (TA184)

Soft tissue sarcoma - trabectedin (TA185)

Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)

Gastric cancer (advanced) - capecitabine (TA191)

Lung cancer (non-small-cell, first line) - gefitinib (TA192)

Leukaemia (chronic lymphocytic, relapsed) - rituximab (TA193)

Gastrointestinal stromal tumours - imatinib (adjuvant) (TA196)

Hepatitis C - peginterferon alfa and ribavirin (TA200) (read in conjunction with TA75 & TA106)

Gastric cancer (HER2-positive metastatic) - trastuzumab (TA208)

Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib (TA209) (part review of TA86)

Colorectal cancer (metastatic) - bevacizumab (TA212)

Breast cancer - bevacizumab (in combination with a taxane) (TA214) (replaces TA147)

Renal cell carcinoma (1st line metastatic) - pazopanib (TA215)

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (TA216)

Myelodysplastic syndrome - azacitidine (TA218)

Lymphoma (follicular non-Hodgkin's) - rituximab (TA226)

Multiple myeloma (1st line) - bortezomib and thalidomide (TA228)

Osteosarcoma - mifamurtide (TA235)

Follicular lymphoma - rituximab (review TA110) (TA243)

Multiple sclerosis (relapsing-remitting) - fingolimod (TA254)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)

Bevacizumab in combination with paclitaxel & carboplatin for 1st line treatment of advanced ovarian cancer (TA284)

Ovarian, fallopian tube & primary peritoneal cancer - bevacizumab (TA285)

Hepatitis C (children and young people) - peginterferon alfa & ribavirin (TA300)

Multiple sclerosis (relapsing) - teriflunomide (TA303)

Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Multiple myeloma - bortezomib (induction therapy) (TA311)

MFT Formulary v10.5 (May 2025) Section 8 Malignant disease Multiple sclerosis (relapsing-remitting) - alemtuzumab (TA312) pilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319) Dimethyl fumarate for treating relapsing-remitting multiple sclerosis (TA320) Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA321) Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5g cytogenetic abnormality (TA322) Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of TA196) (TA326) Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333) Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343) Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non small cell lung cancer (TA347) Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357) Idelalisib for treating chronic lymphocytic leukaemia (TA359) Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366) Bortezomib for previously untreated mantle cell lymphoma (TA370) Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (TA374) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377) Nintedanib for treating idiopathic pulmonary fibrosis (TA379) Panobinostat for treating multiple myeloma after at least 2 previous treatments (TA380) Olaparib forovarian, fallopian tube and peritoneal cancer (TA381) Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384) Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386) Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387) Topotecan, PLDH, paclitaxel, trabectedin & gemcitabine for recurrent ovarian cancer (TA389) Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391) Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (TA395) Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396) Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400) Bosutinib for previously treated chronic myeloid leukaemia (TA401) Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402) Degarelix for treating advanced hormone-dependent prostate cancer (TA404) Trifluridine-tipiracil for previously treated metastatic colorectal cancer (TA405) Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406) Pegaspargase for treating acute lymphoblastic leukaemia (TA408) Talimogene laherparepyec for treating unresectable metastatic melanoma (TA410) Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412) Nivolumab for previously treated advanced renal cell carcinoma (TA417) Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421) Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422) Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423) Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424) Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425) Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426) Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427) Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428) Everolimus for advanced renal cell carcinoma after previous treatment (TA432) Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439) Everolimus & sunitinib for treating unresectable or metastatic neuroendocrine tumours (TA449) Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)

Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (TA458)

Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)

Cabozantinib for previously treated advanced renal cell carcinoma (TA463)

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (replaces TA172) (TA473)

Sorafenib for treating advanced hepatocellular carcinoma (replaces TA189) (TA474)

Paclitaxel with gemcitabine for untreated metastatic pancreatic cancer (replaces TA360) (TA476)

Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

Immunosuppressive therapy for kidney transplant in adults (replaces TA85) (TA481)

Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99) (TA482)

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Cladribine tablets for treating relapsing-remitting multiple sclerosis (TA493)

Palbociclib for previously untreated, locally advanced or metastatic breast cancer (TA495)

Ribociclib for previously untreated, locally advanced or metastatic breast cancer (TA496)

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)

Ibrutinib for treating relapsed or refractory mantle cell lymphoma (TA502)

Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (TA503)

Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)

Tivozanib for treating advanced renal cell carcinoma (TA512)

Obinutuzumab for untreated advanced follicular lymphoma (TA513)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (replaces TA250) (TA515)

Cabozantinib for treating medullary thyroid cancer (TA516)

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma (TA519)

Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (TA520)

Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA522)

Midostaurin for untreated acute myeloid leukaemia (TA523)

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (replaces TA446) (TA524)

Atezolizumab for treating locally advanced or metastatic urothelial carcinoma (TA525)

Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

Beta interferons and glatiramer acetate for treating multiple sclerosis (replaces TA32) (TA527)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA528)

Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer (TA530)

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Ocrelizumab for treating relapsing-remitting multiple sclerosis (TA533)

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Dinutuximab beta for treating neuroblastoma (TA538)

Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia (TA541)

Cabozantinib for untreated advanced renal cell carcinoma (TA542)

Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Padeliporfin for untreated localised prostate cancer (TA546)

Vandetanib for treating medullary thyroid cancer (TA550)

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia (TA552)

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma (TA559)

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Abemaciclib for previously untreated, locally advanced or metastatic breast cancer (TA563)

Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (TA569)

Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (TA577)

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA579)

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity (TA589)

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA598)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA600)

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer (TA612)

Cladribine for treating relapsing-remitting multiple sclerosis (TA616)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

Peginterferon beta-1a for treating relapsing-remitting multiple sclerosis (TA624)

Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)

Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)

Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (replacing TA472) (TA629)

Larotrectinib for treating NTRK fusion-positive solid tumours (TA630)

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632)

Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer (TA638)

Atezolizumab for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (TA639)

Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant (TA640)

Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)

Gilteritinib for treating relapsed or refractory acute myeloid leukaemia (TA642)

Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer (TA643)

Entrectinib for treating NTRK fusion-positive solid tumours (TA644)

Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)

Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma (TA649)

Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)

Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer (replacing TA416) (TA653)

Osimertinib for untreated EGFR mutation-positive NSCLC (replacing TA621) (TA654)

Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy (TA655)

Carfilzomib for previously treated multiple myeloma (replacing TA457) (TA657)

Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma (TA661)

Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer (TA668)

Brigatinib for ALK-positive advanced NSCLC that has not been previously treated with an ALK inhibitor (TA670)

Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma (TA677)

Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

Pembrolizumab with pemetrexed for untreated, metastatic, non-squamous NSCLC (replacing TA557) (TA683)

Nivolumab for adjuvant treatment of completely resected melanoma (replacing TA558) (TA684) Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA687) Acalabrutinib for treating chronic lymphocytic leukaemia (TA689)

Avelumab for untreated metastatic Merkel cell carcinoma (TA691)

Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)

Ofatumumab for treating relapsing multiple sclerosis (TA699)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA704)

Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)

Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA709)

Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy (TA713)

Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with ... (TA716)

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma (TA720)

Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)

Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)

Abemaciclib for treating hormone receptor-positive, HER2-negative advanced breast cancer (updates & replaces TA579) (TA725)

Midostaurin for treating advanced systemic mastocytosis (TA728)

Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck (TA736)

Pembrolizumab for untreated advanced oesophageal & gastro-oesophageal junction cancer (TA737)

Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)

Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)

Nivolumab for adjuyant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)

Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)

Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome (TA754)

Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitable (TA763)

Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)

Ponesimod for treating relapsing-remitting multiple sclerosis (TA767)

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (TA770)

Pembrolizumab for relapsed or refractory classical Hodgkin lymphoma after SCT or at least 2 previous therapies (TA772)

Dostarlimab for previously treated advanced or recurrent endometrial cancer.... (TA779)

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)

Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (TA784)

Tucatinib with trastuzumab & capecitabine for treating HER2-positive advanced breast cancer…. (TA786)

Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer.... (TA788)

Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations (TA789)

Diroximel fumarate for treating relapsing-remitting multiple sclerosis (TA794)

Ibrutinib for treating Waldenstrom's macroglobulinaemia (replacing TA491) (TA795)

Venetoclax for treating chronic lymphocytic leukaemia (replacing TA487) (TA796)

Durvalumab for maintenance treatment of unresectable NSCLC after platinum-based chemoradiation (replacing TA578) (TA798)

Pembrolizumab (plus chemo) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

Cemiplimab for treating advanced cutaneous squamous cell carcinoma (updates & replaces TA592) (TA802) Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease (TA809)

Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer (TA810)

Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer (TA812)

Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors (TA813)

Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817) Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies (TA819)

Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)

Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy (TA827)

Pembrolizumab for adjuvant treatment of renal cell carcinoma (TA830)

Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer (TA836)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)

Cabozantinib for previously treated advanced hepatocellular carcinoma (TA849)

Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer (TA851)

Trifluridine–tipiracil for metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma (replacing TA669) (TA852) Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced NSCLC after platinum-based chemotherapy (TA855)

Nivolumab for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)

Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma (TA858)

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer (TA862)

Nintedanib for treating idiopathic pulmonary fibrosis when FVC is above 80% predicted (partially replaces TA379) (TA864)

Nivolumab for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)

Regorafenib for previously treated metastatic colorectal cancer (TA866)

Ixazomib with lenalidomide & dexamethasone for treating relapsed or refractory multiple myeloma (replacing TA505) (TA870)

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma (replacing TA559) (TA872)

Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma (TA874)

Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer (TA876)

Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy (TA886)

Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia (TA891)

Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia...(TA893)

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma... (TA895)

Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (updates & replaces TA573) (TA897)

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer (TA898)

Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)

Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer (TA904)

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA908)

Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer (TA911)

Pembrolizumab For treating tumours with high microsatellite instability (MSI) or mismatch repair (MMR) deficiency (TA914)

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a SCT is unsuitable (TA917)

Ruxolitinib for treating polycythaemia vera (TA921)

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)

Targeted-release budesonide for treating primary IgA nephropathy (TA937)

Pembrolizumab for persistent, recurrent or metastatic cervical cancer (replaces TA885) (TA939)

Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)

Olaparib with bevacizumab for treatment of advanced high-grade epithelial ovarian, fallopian tube or 1ry peritoneal cancer (TA946)

Loncastuximab tesirine for treating relapsed or refractory DLBCL and HGBCL after 2 or more systemic treatments (TA947)

Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)

Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)

Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations (TA952) Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)

Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer (TA962)

Dostarlimab with platinum-based chemo for advanced / recurrent endometrial cancer with MSI-H or MMR deficiency (TA963)

Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatments (TA970)

Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)

Tisagenlecleucel for treating relapsed or refractory B-cell ALL in people 25 years and under (updates & replaces TA554) (TA975)

Dabrafenib for treating BRAF V600E mutation-positive glioma in children & young people aged 1 year & over (TA977)

Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (TA979)

Pembrolizumab for untreated locally advanced unresectable or metastatic HER2-positive gastric or GOJ adenocarcinoma (TA983)

Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (TA992)

Relugolix for treating hormone-sensitive prostate cancer (TA995)

Pembrolizumab with platinum- and fluoropyrimidine-based chemo for untreated advanced HER2-negative gastric or GOJA (TA997)

Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment (TA1001)

Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)

Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)

Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments (TA1008)

Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

Avapritinib for treating advanced systemic mastocytosis (TA1012)

Quizartinib for treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (TA1013)

Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (TA1014)

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

Pembrolizumab before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable NSCLC (TA1017)

Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (updates & replaces TA756) (TA1018)

Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (updates & replaces TA529) (TA1021) Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

Ublituximab for treating relapsing multiple sclerosis (TA1025)

Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for resectable NSCLC (TA1030)

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy (TA1034)

Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer (TA1036)

Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA1037)

Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug... (TA1038)

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug... (TA1039)

Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy (TA1040)

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA1042)

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (TA1043)

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma (TA1048)

Blinatumomab for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-cell ALL (TA1049) Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

Ruxolitinib for treating acute GvHD that responds inadequately to corticosteroids in people 12 years and over (TA1054) Rucaparib for treatment of advanced ovarian, fallopian tube & peritoneal cancer... (TA1055)

Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma (TA1059)


GMMMG Formulary

Formulary Homepage

Chapter 8: Malignant disease & immunosuppression

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



PbR X NICE iniection BNF emc®

MHRA Drug Safety Update (Oct-20): 5-fluorouracil (IV), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at risk of severe & fatal toxicity Gemcitabine RESTRICTED RED **Haematology Consultants only** PbR X NICE infusion BNF emc® Mercaptopurine RED oral suspension; tablets (see also section 1.5.3) BNF emc Methotrexate infusion; injection; oral solution; tablets (see sections 1.5.3, 10.1.3 & 13.5.3) MMC BNF emc MHRA Drug Safety Update (Aug-23): Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions **Pemetrexed**

RESTRICTED Respiratory RED 🖭 Consultants only in line with TA402

blueteq PBRX NICE MMC BNF CMC

8.1.4 Vinca alkaloids & etoposide **Etoposide RESTRICTED Haematology Consultants only**

capsules; infusion BNF emc Vinblastine sulfate RESTRICTED **Haematology Consultants only**


BNF emc iniection Vincristine sulfate **RESTRICTED** RED **Haematology Consultants only** BNF emc®

8.1.5 Other antineoplastic drugs Acalabrutinib

RESTRICTED RED ££ **Haematology Consultants only** blueteq PBRX NICE MMC BNF emc


Arsenic trioxide **RESTRICTED** Haem. Consultants RED ££ only / also in line with NICE TA526 blueteq infusion PBR X NICE MMC BNF emc

iiii 1 1 oriiialary 1 roto (may 2020)	00000000	mangnant alcoacc
Asciminib RED EE	blueteq	RESTRICTED Haem. Consultants in line with NICE TA813
Scemblix ® 20mg/40mg tablets Asparaginase	PDRX NICE MMC BNF EMC®	RESTRICTED
RED	EARL	Haematology Consultants only
infusion	MMC BNF emc	
Axicabtagene ciloleucel	blueteq	RESTRICTED in line with NICE TA872
Yescarta ® infusion Bevacizumab	PBR X NICE MMC BNF @MC®	DESTRICTED
RED EE	blueteq	RESTRICTED Haematology Consultants only
Avastin® 100mg in 4mL vial	PBR X MMC BNF emc	
Bortezomib RED £	blueteq	RESTRICTED Haematology Consultants only
injection	PBRX NICE MMC BNF EMC®	
Brentuximab vedotin		RESTRICTED Haematology Consultants only
	blueteq	Haematology Consultants only
Brexucabtagene autoleucel	PBRX NICE MMC BNF emc	RESTRICTED Haem, Consultants
RED EE	blueteq	only in line with NICE / CDF
Tecartus ® infusion Cabozantinib	PBRX NICE MMC BNF @MC®	DECEMBER Conscioling Conscioling
RED EE	blueteq	RESTRICTED Specialist Consultant use only in line with NICE
tablets; capsules Carfilzomib	PBRX NICE MMC BNF EMC®	NOT STOCKED
RED EE	blueteq	RESTRICTED Haematology Consultants only in line with NICE
infusion	PBRX NICE MMC BNF (emco)	
Ceritinib RED E	blueteq	RESTRICTED Respiratory Consultants only in line with NICE
capsules Cetuximab	PBRX NICE MMC BNF EMC®	NOT STOCKED
RED EF	blueteq	RESTRICTED Haematology Consultants only in line with NICE
infusion Crisantaspase	PBRX NICE MMC BNF emc	DESTRICTED
RED ED injection	BNF (emco	RESTRICTED Haematology Consultants only
Dacarbazine RED	Sino	RESTRICTED
injection	BNF emco	Haematology Consultants only
Durvalumab		RESTRICTED Respiratory
RED (££) infusion	bluefeq PER X NICE MMC BNF @mc@	Consultants only in line with NICE
Entrectinib		RESTRICTED Specialist Consultant
RED (££) injection	PBRX NICE MMC BNF @mc	use only in line with NICE
Eribulin	www.	RESTRICTED Specialist Consultant
RED ff	DIUGTEQ PER X NICE MMC BNF EMC	use only in line with NICE NOT STOCKED
Erlotinib RED (£)		RESTRICTED Respiratory Consultants only in line with NICE
tablets	PHONE RAPAS	NOT STOCKED
Everolimus RED (£)	(PBR X) NICE) MMC BNF (EMCO)	RESTRICTED Specialist Consultant
tablets	PbR X NICE MMC BNF @CC	use only in line with NICE NOT STOCKED
Hydroxycarbamide AMBER	mino Mino	RESTRICTED Haematology Consultants only
capsules; tablets (see GMMMG below)	BNF emc®	
Hydroxycarbamide RED		RESTRICTED Paediatric patients with swallowing
Xromi® oral liquid Ipilimumab	MMC BNF emc	difficulties RESTRICTED Dermatology
RED (I)	PERX NICE MMC BNF emc	Consultants only in line with NICE NOT STOCKED
MHRA Drug Safety Update (Jan-19): Ipilimumab (Yervoy): reports of		
Ivosidenib RED (£)	blueteq	RESTRICTED Haematology Consultants only in line with NICE
	Dineit±•	



Lenvatinib RED FF Kisplyx® capsules Lenvatinib Lenvima® capsules MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection Loncastuximab tesirine Zynlonta® infusion Mobocertinib RED EE Exkivity® capsules Momelotinib RED ££ Omjjara® tablets Neratinib RED E Nerlyny® tablets **Nilotinib** Tasigna® capsules MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation **Osimertinib** RED (££) Tagrisso® tablets **Palbociclib** Ibrance ® capsules MHRA Drug Safety Update (Jun-21): CDK4/6 inhibitors (abemaciclib ▼, palbociclib ▼, ribociclib ▼): reports of ILD & pneumonitis, including severe cases **Ponatinib** Iclusia® tablets MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection MHRA Drug Safety Update (Oct-18): Ponatinib (Iclusig ▼): reports of posterior reversible encephalopathy syndrome MHRA Drug Safety Update (May-16): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation MHRA Drug Safety Update (Nov-14): Ponatinib (Iclusig ▼): risk of vascular occlusive events Quizartinib dihydrochloride RED £ Vanflyta® tablets PBRX NICE MMC BNF emc Regorafenib **RESTRICTED** Specialist use only in line with NICE TA488 / TA555 blueteq **NOT STOCKED** Stivarga® 40mg tablets PBRX NICE MMC BNF CMC MHRA Drug Safety Update (Jul-20): Systemically administered VEGF pathway inhibitors: risk of aneurysm and artery dissection © Manchester University NHS Foundation Trust 2025

RESTRICTED **Haematology Consultants only** Infusion PBRX NICE MMC BNF emc MHRA Drug Safety Update (Jan-22): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error Cabazitaxel **RESTRICTED** RED EE **Haematology Consultants only** blueteq Jevtana® Infusion PBRX NICE MMC BNF emc



Bacillus Calmette-Guérin

Bacillus Calmette-Guérin

BCG-medac® intravesical suspension

OncoTICE® bladder instillation

RESTRICTEDSpecialist use only

RESTRICTED
Specialist use only

BNF emc

MMC BNF emc



tablets Thalidomide

capsules

PBRX NICE MMC BNF emc

PBRX NICE MMC BNF emc


NOT STOCKED

RESTRICTED Haematology **Consultants only**


MHRA Drug Safety Update (May-20): Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)

MHRA Drug Safety Update (Dec-15): Thalidomide: reduced starting dose in patients older than age 75 years

MHRA Drug Safety Update (May-13): Thalidomide: risk of second primary malignancies



NEW RESTRICTIONS on puberty blockers - Department of Health and Social Care (29 May 2024)



PbR X NICE MMC

emc⊕

Lutathera® injection

NOT STOCKED





Section 9: Nutrition & blood

Supported by the formulary (click here)



9.1 Anaemias and some other blood disorders

- 9.1.1 Iron deficiency anaemias
- 9.1.2 Drugs used in megaoblastic anaemias
- 9.1.3 Drugs used in hypoplastic, haemolytic & renal anaemias
- 9.1.4 Drugs used in autoimmune thrombocytopenic purpura
- 9.1.6 Drugs used in neutropenia
- 9.1.7 Drugs used to mobilise stem cells
- 9.1.8 Haemophilia B

9.2 Fluids and electrolytes

- 9.2.1 Oral preparations for fluid & electrolyte imbalance
- 9.2.2 Parenteral preparations for fluid & electrolyte imbalance
- 9.3 Intravenous nutrition

9.4 Oral nutrition

9.4.1 Nutrition in special diets

9.5 Minerals

- 9.5.1 Calcium and magnesium
- 9.5.2 Phosphorus
- 9.5.3 Fluoride
- 9.5.4 Zinc

9.6 Vitamins

- 9.6.1 Vitamin A
- 9.6.2 Vitamin B group
- 9.6.3 Vitamin C (Ascorbic acid)
- 9.6.4 Vitamin D
- 9.6.5 Vitamin E (Tocopherols)
- 9.6.6 Vitamin K
- 9.6.7 Multivitamin preparations

9.7 Bitters & tonics

9.8 Metabolic disorders

- 9.8.1 Drugs used in metabolic disorders
- 9.8.2 Acute porphyrias

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Nutrition support in adults (CG32)

Coeliac disease: recognition, assessment and management (NG20)

Chronic kidney disease: assessment and management (NG203)

Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)

Migalastat for treating Fabry disease (HST4)

Eliglustat for treating type 1 Gaucher disease (HST5)

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

Elosulfase alfa for treating mucopolysaccharidosis type 4A (HST19)

Asfotase alfa for treating paediatric-onset hypophosphatasia (replacing HST6) (HST23)

Lumasiran for treating primary hyperoxaluria type 1 (HST25)

Hyperparathyroidsim - cinacalcet (TA117)

Thrombocytopenic purpura - romiplostim (TA221)

Thrombocytopenic purpura - eltrombopag (TA293)

Erythropoiesis-stimulating agents (epoetin & darbepoetin) for treating anaemia in chemotherapy (TA323)

Etelcalcetide for treating secondary hyperparathyroidism (TA448)

Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

Patiromer for treating hyperkalaemia (TA623)

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

Caplacizumab for treating acute acquired thrombotic thrombocytopenic purpura (TA667)

Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)

Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)

Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)

Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)

Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)

Avalglucosidase alfa for treating Pompe disease (TA821)

Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease (TA912)

Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)

Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)

Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)

Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)

Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)


GMMMG Formulary


Formulary Homepage

Chapter 9: Nutrition & Blood

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List






PBRX NICE MMC BNF emc

Nplate ® injection





Bicarbonate and lactate		
Sodium bicarbonate		
1.26%, 2.74%, 4.2% & 8.4% injection; infusion	BNF emco	
Sodium lactate compound		
•	EXVID	
(Hartmann's solution) infusion	BNF emc	
Water		
Water for Injections		
•		
injection	emc⊚	
9.2.2.2 Plasma & plasma substitutes	<u>emo</u>	
Dextran		
Dextran 40 - 10% in sodium chloride 0.9% infusion	emc ⊚	
Dextrose Acid Citrate ACDA	CINO	
2000 7000 7000 7027		
solution		
Gelatin	<u>emc</u> ⊚	
Geraum		
	ES N I I I I I I I I I I I I I I I I I I	
Gelofusine® infusion	BNF emc	

9.3 Intravenous nutrition

BNF








Prescribers should seek advice from the MFT Nutrician Support Team (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)

NICE CG32

9.4 Oral nutrition				Gм <mark>₩</mark> мG
Prescribers should seek advice from the MFT Nutrician Support Te (pager service 07659 526240) or the Dietetic Support Teams (General x64668; Renal x64478; Gastro x65781)	eam			NICE CG32
9.4.1 Nutrition in special diets				
Sapropterin dihydrochloride RED EE		Bj V 5 ortobildren	blueteq	RESTRICTED Tetrahydrobiopterin deficiency
Kuvan® 100mg soluble tablets	RX	MMC BNF	emc ⊕	England
LaBiNIC® probiotic drops				RESTRICTED
				prevention of NEC
LaBiNIC® probiotic drops	ı	MMC	emc _®	








9.6.6 Vitamin K	
Phytomenadione	
GREEN	F N F
Konakion® MM & Konakion® MM Paediatric injection	MMC BNF emc
Menadiol sodium phosphate	
GREEN	F N F
oral solution; tablets	MMC BNF emc
9.6.7 Multivitamin preparations	
Vitamins B,C	RESTRICTED
Renavit® tablets	MMC BNF emc
Vitamins A,D,E,K	RESTRICTED
GREY SI	Paediatric CF patients
Paravit-CF® capsules; liquid	MMC BNF emc

9.7 Bitters & tonics




Mixtures containing simple and aromatic bitters are traditional remedies for loss of appetite; there is no evidence to support their use




PbR X

MMC BNF emc

capsules; oral suspension





Section 10: Musculoskeletal & joint diseases

Supported by the formulary (click here)



10.1 Drugs used in rheumatic diseases & gout

10.1.1 Non-steroidal anti-inflammatory drugs

10.1.2 Corticosteroids

10.1.3 Drugs that suppress the rheumatic disease process

Gold

Penicillamine

Antimalarials

Drugs affecting the immune response

Cytokine modulators

10.1.4 Gout and cytotoxic induced hyperuricaemia

10.1.5 Other drugs for rheumatic diseases

10.2 Drugs used in neuromuscular disorders

10.2.1 Drugs that enhance neuromuscular transmission

10.2.2 Skeletal muscle relaxants

Nocturnal leg cramps

10.2.3 Drugs used in neuromuscular disorders

10.3 Drugs for the relief of soft-tissue inflammation

10.3.1 Enzymes

10.3.2 Rubefacients & other topical antirheumatics

10.4 Miscellaneous preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Rheumatoid arthritis in adults: management (NG100)

Osteoarthritis in over 16s: diagnosis and management (NG226)

Onasemnogene abeparvovec for treating spinal muscular atrophy (HST15)

Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (replacing HST3) (HST22)

Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy (partial update of HST15) (HST24)

Hyperuricaemia - febuxostat (TA164)

Psoriasis - ustekinumab (TA180)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor (TA195)

Psoriatic arthritis - etanercept, infliximab and adalimumab (TA199)

Psoriatic arthritis - golimumab (TA220)

Rheumatoid arthritis (after the failure of previous DMARDs) - golimumab (TA225)

Arthritis (juvenile idiopathic, systemic) - tocilizumab (TA238)

Rheumatoid arthritis - tocilizumab (rapid review TA198) (TA247)

Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

Adalimumab, etanercept, infliximab, certolizumab, golimumab, tocilizumab & abatacept for rheumatoid arthritis (TA375)

TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

Apremilast for treating active psoriatic arthritis (TA433)

Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)

Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (replaces TA89) (TA477)

Tofacitinib for moderate to severe rheumatoid arthritis (TA480)

Sarilumab for moderate to severe rheumatoid arthritis (TA485)

Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)

Autologous chondrocyte implantation using chondrosphere for symptomatic articular cartilage defects of the knee (TA508)

Tocilizumab for treating giant cell arteritis (TA518)

xekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Nusinersen for treating spinal muscular atrophy (TA588)

Upadacitinib for treating severe rheumatoid arthritis (TA665)

Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

Anakinra for treating Still's disease (TA685)

Adalimumab, etanercept, infliximab & abatacept for treating moderate RA after conventional DMARDs have failed (TA715)

Ixekizumab for treating axial spondyloarthritis in adults (TA718)

Secukinumab for treating non-radiographic axial spondyloarthritis in adults (TA719)

Tofacitinib for treating juvenile idiopathic arthritis (TA735)

Upadacitinib for treating moderate rheumatoid arthritis (TA744)

Belimumab for treating active autoantibody-positive systemic lupus erythematosus (replaces TA397) (TA752)

Risdiplam for treating spinal muscular atrophy (TA755)

Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (replacing TA711) (TA815)

Upadacitinib for treating active ankylosing spondylitis (TA829)

Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

Bimekizumab for treating axial spondyloarthritis (TA918)

Tofacitinib for treating active ankylosing spondylitis (TA920)

GMMMG Formulary


Formulary Homepage

Chapter 10: Musculoskeletal & Joint Diseases

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

100mg; 200mg tablets




Section 10

BNF emc




MHRA Drug Safety Update (Sep-20): Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose



NICE MMC BNF emc tablets MHRA Drug Safety Update (May-23): Febuxostat: updated advice for the treatment of patients with a history of major cardiovascular disease MHRA Drug Safety Update (Jul-19): Febuxostat: increased risk of CV death and all-cause mortality in clinical trial in patients with a history of major CV disease MHRA Drug Safety Update (Jun-12): Febuxostat (Adenuric ▼): stop treatment if signs or symptoms of serious hypersensitivity Hyperuricaemia associated with cytotoxic drugs


Rasburicase **RESTRICTED** RED ££ **Haematology Consultants only** blueteq Fasturtec® infusion PbR X MMC BNF emc

10.1.5 Other drugs for rheumatic diseases NICE CG177 **NICE TA477 NICE TA508**



PBRX NICE MMC BNF emc

oral solution





Non-Formulary Items			G <mark>м</mark> МG
Glucosamine			in line with GMMMG
with or without chondroitin		BNF	
Hyaluronan injections (DNP)			in line with GMMMG
injection including hyaluronan and sodium hyaluronate		BNF	
Naproxen with esomeprazole (DNP)			in line with NICE / GMMMG
		BNF emco	
Satralizumab (DNP)			in line with NICE / GMMMG
Enspryng® injection	NICE	BNF emc	
Sodium aurothiomalate			Discontinued June 2019
injection		BNF emco	

Section 11: Eye

Supported by the formulary (click here)



11.3 Anti-infective eye preparations

- 11.3.1 Antibacterials
- 11.3.3 Antivirals

11.4 Corticosteroid & other anti-inflammatory preparations

- 11.4.1 Corticosteroids
- 11.4.2 Other anti-inflammatory preparations

11.5 Mydriatics & cycloplegics

11.6 Treatment of glaucoma

Beta-blockers

Prostaglandin analogues and prostamides

Combination products (prostaglandin analogue with beta-blocker)

Combination products (prostaglandin analogue with Rho kinase inhibitor)

Sympathomimetics

Carbonic anhydrase inhibitors

Miotics

11.7 Local anaesthetics

11.8 Miscellaneous ophthalmic preparations

- 11.8.1 Tear deficiency, ocular lubricants & astringents
- 11.8.2 Ocular diagnostic & peri-operative preparations & photodynamic treatment
- 11.8.3 Other preparations

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Glaucoma: diagnosis and management (NG81)

Age-related macular degeneration (NG82)

Diabetic retinopathy: management and monitoring (NG242)

Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations (HST11)

Macular degeneration (age related) ranibizimab & pegaptanib (TA155)

Macular oedema (retinal vein occlusion) - dexamethasone (TA229)

Macular oedema (diabetic) - ranibizumab (TA274)

Macular oedema (retinal vein occlusion) - ranibizumab (TA283)

Macular degeneration (wet age-related) - aflibercept (1st line) (TA294)

Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298)

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305)

Aflibercept for treating diabetic macular oedema (TA346)

Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (TA369)

Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)

Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)

Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

Aflibercept for treating choroidal neovascularisation (TA486)

Cenegermin for treating neurotrophic keratitis (TA532)

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uvetitis (TA590)

Brolucizumab for treating wet age-related macular degeneration (TA672)

Faricimab for treating diabetic macular oedema (TA799)

Faricimab for treating wet age-related macular degeneration (TA800)

Brolucizumab for treating diabetic macular oedema (TA820)

Dexamethasone intravitreal implant for treating diabetic macular oedema (replacing TA349) (TA824)

Fluocinolone acetonide intravitreal implant for treating chronic DMO (updates & replaces TA301 / TA613) (TA953)

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion (TA1004)

Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (TA1009)

Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)

Tebentafusp for treating advanced uveal melanoma (TA1027)


GMMMG Formulary

Formulary Homepage


Chapter 11: Eye


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List


GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List



Propamidine isetionate RED 0.1% eye drops	RESTRICTED Consultant Ophthalmologist only
Vancomycin (ophthalmic) RED 5% eye drops	RESTRICTED gram positives, including MRSA but not VRE BNF emc NOT STOCKED
11.3.3 Antivirals	
Ganciclovir SI 0.15% eye gel	BNF emc®
Trifluorothymidine U RED 1% eye drops	BNF emc®










11.7 Local anaesthetics	G™MG
Ocular Local anaesthetics	
Fluorescein with lidocaine (minims)	
4% / 0.25% eye drops	emc ⊚
Oxybuprocaine hydrochloride (minims)	<u>Cinco</u>
RED	
0.4% eye drops	emco
Proxymetacaine hydrochloride (minims)	
RED	
0.5% eye drops	emc
Tetracaine (Amethocaine) (minims)	
RED	
1% & 2% eye drops	emc⊚



11.8.2 Ocular diagnostic & peri-operative preparation Ocular diagnostic preparations	ns a photodynamic deadnest	
Ocular diagnostic preparations Fluorescein sodium		
RED SOCIUM		
10/ 9 20/ procentative free eve drape	SINIF for children	
1% & 2% preservative free eye drops Fluorescein sodium	(BNF) emc	RESTRICTED
RED		Specialist use only
400 / / / / /	IS N.E. Recabildan	fundus fluorescein angiography
100mg/mL injection Indocyanine green (ICG)	MMC BNF emco	
RED RED		RESTRICTED Specialist use only
Verte 8 5 - 7 1 1 1 1 1	14140	Specialist use only
Verdye ® 5mg/mL injection Ocular peri-operative drugs	MMC emc⊚	
Acetylcholine chloride		DECEMBER Consultant
Acetylcholine chiloride		RESTRICTED Consultant Ophthalmologist only
400	ISS NUE for children	Ophthalmologist only
1% intraocular irrigation Apraclonidine	BNF emc⊚	DECEMBER OF THE PARTY OF THE PA
SI RED		RESTRICTED Consultant
	I ≥ 3 N . (□ for children	Ophthalmologist only
opidine® 0.5% eye drops; 1% preservative free eye drops Bromfenac	BNF emc	
Sromenac		RESTRICTED Consultant only for pseudophakic CMO
		pseudopnakic CiviO
✓etorslag tramatamal	MMC BNF emco	BEOTE: 0 :: :
Ketorolac trometamol		RESTRICTED Consultant
	ESIN IF	Ophthalmologist only
Acular® 0.5% eye drops	BNF emc®	
Nepafenac		RESTRICTED. 1 st line post cataract
		surgery in diabetics. 2 nd line CMO
Nevanac® 1 mg/mL eye drops	MMC BNF emc	
Povidone-lodine		RESTRICTED Consultant
	(RANN) F	Ophthalmologist only
5% eye drops	MMC BNF emc®	
Heavy Silicone oil		RESTRICTED intraocular tamponado
		of inferior retinal breaks
Densiron® 68 - 10mL syringe	MMC	
Subfoveal choroidal neovascularisation		
Aflibercept RED EE		RESTRICTED Consultant
RED EE		Ophthalmologist only
Eylea® 40mg in 1mL injection	PBRX NICE MMC BNF EMC®	
Bevacizumab U		RESTRICTED Consultant
RED EE	blueteq	Ophthalmologist only
Avastin® 100mg in 4mL vial	PBR X MMC BNF emco	
Bevacizumab gamma		RESTRICTED Consultant
RED EE		Ophthalmologist only
Lytenava® 25 mg/mL injection	PBRX NICE MMC BNF EMC®	
Brolucizumab		RESTRICTED Consultant
RED EE		Ophthalmologist only
Beovu® 120mg in 1mL injection	PBRX NICE MMC BNF EMC®	
MHRA Drug Safety Update (Jan-22): Brolucizumab (Beovu ▼): risk of in	ntraocular inflammation and retinal vascular occlusion increase	
Faricimab RED (£)		RESTRICTED Consultant
NED 22		Ophthalmologist in line with NICE
/abysmo® 120mg/mL injection	PBR X NICE MMC BNF EMC®	TA799 / TA800 / TA1004
Ranibizumab		RESTRICTED Consultant
RED TE		Ophthalmologist only
ucentis® / Ongavia® 10mg/mL injection	PBRX NICE MMC BNF EMC®	Engl
Verteporfin RED (EE)		RESTRICTED Consultant
	_	Ophthalmologist only
Visudyne® 15mg vial	PBR X MMC BNF emco	
Vitreomacular traction		
11.8.3 Other preparations		
Voretigene		
Voretigene neparvovec		RESTRICTED Consultant
RED (£E)	blueteq	Ophthalmologist in line with NICE
<i>Luxturna</i> ® 2mL vial	PBRX NICE MMC emc	
Insulin eye drops		
Insulin (soluble) eye drops (U)		RESTRICTED
NED .		Consultant Ophthalmologist
Humulin S® in Systane® lubricant eye drops	MMC	

Non-Formulary Items		GM <mark>M</mark> MG
Cenegermin		DISCONTINUED January 2020
Oxervate®	NICE	
Commercial eyelid cleansing preparations (DNP)		in line with GMMMG
		Criterion 1
Conjunctivitis (bacterial) (DNP)		in line with GMMMG / NHSE
Chloramphenicol eye drops or ointment. Conjunctivitis (viral) (DNP)		in line with GMMMG / NHSE
Dry eyes / sore tired eyes (DNP)		in line with GMMMG / NHSE
Hypromellose eye drops, carbomer 980 gel, hyaluronate eye drops		
Ocriplasmin RED (ff)		DISCONTINUED May 2020
Jetrea® 0.5mg/0.2mL injection	PBRX NICE MMC BNF EMC	
Polymyxin B sulfate Polyfax® eye ointment	BNF emco	DISCONTINUED November 2017
Poly (carboxymethylglucose sulfate)	<u> </u>	DISCONTINUED
, , , , , , , , , , , , , , , , , , , ,		December 2019
Cacicol® eye drops (0.33mL)	MMC BNF emc	
Simple eye ointment (DNP)		in line with GMMMG
	BNF emco	Criterion 1
Tebentafusp Red (££)		NOT STOCKED. Patients treated at commissioned centre in Liverpool
Kimmtrak ® 200micrograms/mL infusion	PBRX NICE MMC BNF CMC	·

Section 12: Ear, nose & oropharynx

Supported by the formulary (click here



- 12.1 Drugs acting on the ear
 - 12.1.1 Otitis externa
 - 12.1.3 Removal of ear wax
- 12.2 Drugs acting on the nose
 - 12.2.1 Drugs used in nasal allergy
 - 12.2.2 Topical nasal decongestants
 - 12.2.3 Nasal preparations for infection
- 12.3 Drugs acting on the oropharynx
 - 12.3.1 Drugs for oral ulceration & inflammation
 - 12.3.2 Oropharyngeal anti-infective drugs
 - 12.3.4 Mouthwashes, gargles & dentifrices
 - 12.3.5 Treatment of dry mouth

Non-Formulary Items

Trust Guidelines

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Sinusitis (acute): antimicrobial prescribing (NG79) Sore throat (acute): antimicrobial prescribing (NG84) Otitis media (acute): antimicrobial prescribing (NG91) Tinnitus: assessment and management (NG155) Otitis media with effusion in under 12s (NG233)


Allergic rhinitis (CKS)


GMMMG Formulary


Formulary Homepage

Chapter 12: Ear, nose & oropharynx

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List







Non-Formulary Items	GMMG
Acute sore throat (DNP)	in line with GMMMG
Sore throat lozenges and sprays, analgesics	
Coughs, colds and nasal congestion (DNP)	in line with GMMMG
seudoephedrine nasal sprays and oral preparations. Xylometazoline and ephedrine nasal sprays and drops	
Ear wax removal	in line with GMMMG
Dlive oil, sodium bicarbonate ear drops. Includes prior to syringing	
Mouth ulcers (DNP)	in line with GMMMG
Local anaesthetic gels, hydrocotrisone buccal tablets	
Oral thrush (DNP)	in line with GMMMG
ficonazole oral gel. nystatin oral suspension	

Section 13: Skin

Supported by the formulary (click here)



- 13.2 Emollient & barrier preparations
 - 13.2.1 Emollients
 - 13.2.2 Barrier preparations
- 13.3 Topical local anaesthetics & antipruritics
- 13.4 Topical corticosteroids
- 13.5 Preparations for eczema & psoriasis
 - 13.5.1 Preparations for eczema
 - 13.5.2 Preparations for psoriasis
 - 13.5.3 Drugs affecting the immune response Cytokine Modulators
- 13.6 Acne & Rosacea
 - 13.6.1 Topical preparations for acne
 - 13.6.2 Oral preparations for acne
- 13.7 Preparations for warts & calluses
- 13.8 Sunscreens & camouflagers
 - 13.8.1 Sunscreen preparations
- 13.9 Shampoos & other preparations for scalp/hair conditions
- 13.10 Anti-infective skin preparations
 - 13.10.1 Antibacterial preparations
 - 13.10.2 Antifungal preparations
 - 13.10.3 Antiviral preparations
 - 13.10.4 Parasiticidal preparations
 - 13.10.5 Preparations for minor cuts & abrasions
- 13.11 Skin cleansers, antiseptics & desloughing agents
 - 13.11.1 Alcohols & saline
 - 13.11.2 Chlorhexidine salts
 - 13.11.4 lodine
 - 13.11.6 Oxidisers & dyes
 - 13.11.7 Desloughing agents
- 13.12 Antiperspirants
- 13.13 Topical circulatory preparations
- 13.14 Miscellaneous preparations
- Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Biosimilar Medicines (KTT15)

Atopic eczema in children (CG57)

Psoriasis: assessment and management (CG153)

Pressure Ulcers (CG179)

Pubic lice CKS (2011)

Scabies CKS (2011)

Acne vulgaris CKS (2014)

Head lice CKS (2015)

Surgical site infections: prevention and treatment (NG125)

Atopic dermatitis (eczema) - topical steroids (TA81)

Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)

Psoriasis - efalizumab and etanercept (TA103)

Psoriasis - infliximab (TA134)

Psoriasis - adalimumab (TA146)

Alitretinoin for the treatment of severe chronic hand eczema (TA177)

Psoriasis - ustekinumab (TA180)

Melanoma (stage III or IV) - ipilimumab (TA268)

Melanoma (BRAF V600 mutation positive, unresectable metastatic) - vemurafenib (TA269)

Ustekinumab for treating active psoriatic arthritis (rapid review of TA313) (TA340)

Secukinumab for treating moderate to severe plaque psoriasis (TA350)

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

Apremilast for treating moderate to severe plaque psoriasis (replaces TA368) (TA419)

Apremilast for treating active psoriatic arthritis (TA433)

Ixekizumab for treating moderate to severe plaque psoriasis (TA442)

Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

Dimethyl fumarate for treating moderate to severe plague psoriasis (TA475)

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Guselkumab for treating moderate to severe plague psoriasis (TA521)

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Certolizumab pegol for treating moderate to severe plague psoriasis (TA574)

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Baricitinib for treating moderate to severe atopic dermatitis (TA681)

Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)

Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)

Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837) Difelikefalin for treating pruritus in people having haemodialysis (TA890)

Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)

Bimekizumab for treating active psoriatic arthritis (TA916)

Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)

Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)

Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)

GMMMG Formulary


Formulary Homepage


Chapter 13: Skin

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

EMA (efalizumab)





13.4 Topical corticosteroids GMMMGCorticosteroid only preparations NICE TA81 MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions MHRA Drug Safety Update (Aug-17): Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration **HYDROCORTISONE Potency** Canesten HC® Mild GREEN hydrocortisone 1% plus clotrimazole 1% cream BNF emce Daktacort® Mild hydrocortisone 1%, miconazole nitrate 2% cream; ointment BNF emc Eurax-hydrocortisone® Mild hydrocortisone 0.25%, crotamiton 10% cream BNF emc® Fucidin H® Mild GREEN hydrocortisone 1%, fusidic acid 1% cream BNF emc Terra-Cortril® Mild hydrocortisone 1%, oxytetracycline 3% ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate Moderate GREEN betamethasone valerate 0.025% ointment, cream BNF emc Betnovate-RD® Moderate GREEN betamethasone valerate 0.025% cream: ointment BNF emc **CLOBETASONE BUTYRATE Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions **Eumovate**® **Moderate** Clobetasone butvrate 0.05% cream: ointment BNF emc **BETAMETHASONE ESTERS Potency** MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling, reminder of possible severe side effects, including withdrawal reactions MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk of topical steroid withdrawal reactions Betamethasone valerate **Potent** GREEN betamethasone valerate 0.1% ointment; cream; lotion; scalp lotion BNF emc Betnovate® **Potent** GREEN Betamethasone valerate 0.1% cream; ointment; scalp application; lotion BNF emc Betamethasone valerate with clioquinol **Potent** BNF emc betamethasone valerate 0.1% / clioquinol 3% ointment; cream Betamethasone valerate with neomycin sulfate Potent betamethasone valerate 0.1% / neomycin sulfate 0.5% cream; ointment BNF emc® Diprosalic ® Potent Betamethasone dipropionate 0.05%, salicylic acid 3% ointment BNF emc Fucibet® **Potent** GREEN betamethasone valerate 0.1% plus fusidic acid 2% cream BNF emc Betnovate® Potent


betamethasone valerate ointment 25% in coal tar

DERMATOLOGY ONLY

CLOBETASOL PROPIONATE		Potency
MHRA Drug Safety Update (May-24): Topical steroids: introduction of new labelling,	reminder of possible severe side effects, including wit	thdrawal reactions
MHRA Drug Safety Update (Sep-21): Topical corticosteroids: information on the risk	of topical steroid withdrawal reactions	
Dermovate®		
GREEN	ES N.C.	Very potent
clobetasol propionate 0.05% ointment; cream; lotion; scalp lotion	BNF emc	
Dermovate NN®		
	ENVE	Very potent
clobetasol propionate 0.05% / neomycin sulfate / nystatin cream	BNF emc	
Etrivex ®		
GREEN		Very potent
elobetasol propionate 500micrograms/g shampoo	MMC BNF emc	RESTRICTED - 1 ^{ry} Care referral
DIFLUCORTOLONE VALERATE		Potency
Diflucortolone valerate 0		Very potent
diflucortolone valerate 0.3% oily cream	MMC emc	RESTRICTED Consultant Gynaecologist


13.5 Preparations for eczema & psoriasis GMMMG13.5.1 Preparations for eczema Alitretinoin RESTRICTED **Dermatology Consultants only** PBRX NICE MMC BNF CMC MHRA Drug Safety Update (Jul-21): Oral retinoid medicines (isotretinoin ▼, alitretinoin ▼ & acitretin ▼): temporary monitoring advice during COVID-19 pandemic MHRA Drug Safety Update (Jun-19): Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals & women 13.5.2 Preparations for psoriasis Topical preparations for psoriasis NICE CG153 Calcipotriol RESTRICTED GREEN **Dermatology Consultants only** BNF emc Dovonex® ointment: with Betamethasone (Dovobet® 0.05% ointment) **Dithranol RESTRICTED Dermatology Consultants only** Dithocream ® 0.1% & 0.25% cream BNF emc Salicylic acid **RESTRICTED Dermatology Consultants only** Zinc & Salicylic acid paste BP (Lassar's Paste) BNF emc **Tacalcitol** RESTRICTED **Dermatology Consultants only** Curatoderm® lotion: ointment BNF emc Tars Coal tar paste BP RESTRICTED **Dermatology Consultants only** BNF emc Coal tar with salicylic acid and precipitated sulfur RESTRICTED **Dermatology Consultants only** Cocois® scalp ointment BNF emc Oral retinoids for psoriasis Acitretin RESTRICTED RED **Dermatology Consultants only** 10mg; 25mg capsules BNF emc Dimethyl fumarate **Dimethyl fumarate** RESTRICTED RED ££ 3rd/4th line as per NICE/GMMMG blueteq **Referral to SRFT** 30mg; 120mg tablets PBR X NICE MMC BNF emc 13.5.3 Drugs affecting the immune response **Abrocitinib RESTRICTED Dermatology Consultants only** blueteq in line with NICE Cibingo ® 50mg; 100mg; 200mg tablets PBRX NICE MMC BNF CMC MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality **Azathioprine RESTRICTED Dermatology Consultants only** 25mg; 50mg tablets (see also sections 1.5.3, 8.2.1 & 10.1.3) BNF emc Ciclosporin **RESTRICTED Dermatology Consultants only PRESCRIBE BY BRAND** 25mg, 50mg & 100mg caps; 100mg/1mL oral soln; Infusion (see also section 8.2.2) PbR X MMC BNF emc Methotrexate RESTRICTED **Dermatology Consultants only** 2.5mg tablets (see also sections 8.1.3 & 10.1.3) MMC BNF emc **Pimecrolimus RESTRICTED Dermatology Consultants only** 1% cream NICE MMC BNF emc Sirolimus RESTRICTED **Dermatology Consultants only** Hyftor® 0.2% gel (see also section 8.2.2) MMC BNF emc® Tacrolimus (specially made by SRFT) **RESTRICTED Dermatology Consultants only** 0.03%; 0.1% ointment (see also section 8.2.2) PBRX NICE MMC BNF emco Upadacitinib **RESTRICTED Dermatology Consultants only** blueteq in line with NICE Rinvoq® 15mg; 30mg MR tablets (see also sections 1.5.3 & 10.1.3) PBRX NICE MMC BNF emc

MHRA Drug Safety Update (Apr-23): JAK inhibitors: new measures to reduce risks of major CV events, malignancy, VTE, serious infections and increased mortality





PBRX NICE MMC BNF emc


Wezenla® injection (see also sections 1.5.3 & 10.1.3)



MHRA Drug Safety Update (Dec-14): Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders








13.10 Anti-infective skin preparations GM<mark>M</mark>MG 13.10.1 Antibacterial preparations Topical antibacterials should generally be avoided for the treatment of infections 13.10.1.1 Antibacterial preparations only used topically Mupirocin 2% cream; ointment MMC BNF emc Fusidic acid **RESTRICTED** superficial impetigo 2% cream: ointment BNF emc Metronidazole RESTRICTED GREEN topical treatment of rosacea 0.75% topical gel; cream BNF emc® Silver sulfadiazine **RESTRICTED** GREEN Treatment/prophylaxis of burns 1% w/w cream BNF emc 13.10.2 Antifungal preparations **Amorolfine** 1st line antifungal for nail infections 5% nail lacquer MMC BNF emc® Benzoic acid with salicylic acid 1st line treatment of ringworm benzoic acid 6% / salicylic acid 3% / in emulsifying ointment BNF emc Clotrimazole 1st line GREEN OTC fungal skin infections 1% cream BNF emc® Miconazole 2nd line GREEN OTC fungal skin infections BNF emc 2% cream Terbinafine 2nd line GREEN OTC fungal skin infections 1% cream BNF emc 13.10.3 Antiviral preparations Aciclovir 1st line GREEN OTC 5% cream (see also section 5.3.2.1) BNF emc 13.10.4 Parasiticidal preparations NICE CKS: Head lice NICE CKS: Pubic lice **NICE CKS: Scabies** Ivermectin (1) MMC BNF emc® Malathion 0.5% aqueous solution BNF emc Permethrin GREEN BNF emc MHRA Drug Safety Update (Mar-18): Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition. 13.10.5 Preparations for minor cuts & abrasions **Brulidine RESTRICTED** Theatres only 0.15% w/w cream emc_® Preparations for boils Magnesium sulfate naste RP BNF emc® Skin tissue adhesive Histoacryl® **RESTRICTED** Theatres only

0.5mL skin adhesive

BNF emc®





13.13 Topical circulatory preparations	G <mark>м</mark> MG	
Topical circulatory preparations		
Heparinoid		
Hirudoid® 0.3% cream: 0.3% gel	RNE emco	

13.14 Miscellaneous preparations				GM <mark>M</mark> MG	
8-Methoxypsoralen				RESTRICTED Dermatology Consultants only	
10mg tablets		MMC	emc _®		
Fumaric acid esters				RESTRICTED Dermatology Consultants only	
Fumaderm® tablets		MMC	emc _®		
Glucarpidase ①		[8]	NF	RESTRICTED 2 nd line rescue therapy	
Voraxaze® 1,000 unit injection (see also sections 1.10, 8.4 & 10.4)	PbR X	MMC 🔠	VF emc	E	NHS England
Hyaluronic acid with lidocaine 0				RESTRICTED vocal cord paralysis	
Juvederm® / Belotero® injection		MMC	emc _®		

in line with GMMMG / NHSE and cap feel with question and cap state processors in line with GMMMG / NHSE	Non-Formulary Items	GM <mark>M</mark> MG
Commonweal of the collection	Bio-oil® (DNP) OTC	in line with GMMMG
in line with GMMMG / NHSE cocycholic acid corrected special to separate solution to signature corrected special to separate solution corrected special to separate s	(DNP) OTC	in line with GMMMG / NHSE
September 2019 (September 2019) September 2019 September 2019 September 2019 September 2019 In line with GMMMG In line with GMMMG / NHSE	andruff	in line with GMMMG / NHSE
DISCONTINUED September 2021 DISCONTINUED September 2021 In line with GMMMG In line with GMMMG In line wit	(DNP)	
In line with GMMMG / NHSE coessive sweating (hyperhidrosis) coessive sweating (hyperhidrosis) coessive sweating (hyperhidrosis) in line with GMMMG / NHSE and line with GMMMG / NHSE and line with GMMMG / NHSE and line with GMMMG / NHSE in line with GMMMG / NHSE	iprobase®	DISCONTINUED September 2021
In line with GMMMG / NHSE with an addition of the components of t	mollient bath and shower preparations without antimicrobials	
In line with GMMMG / NHSE metrone, materion, cyclomethicone, permethrin shampoos and liquids. "Bug puster" kts, nit combs. ydrocortisone (mor) Secondarian in dimethryl sufficiation (mor) In line with GMMMG in line with GMMMG / NHSE allow for any or common or c	(DNP) OTC	in line with GMMMG / NHSE
in line with GMMMG Sty crimment, 2.5% cream and originate it footunition in dimethyl sulfoxide (In line with GMMMG Sty crimment, 2.5% cream and originate it forequent cold sores of the lip (In line with GMMMG / NHSE Stocky Cream, Zovinxi0 cold sore cream genol mebutate WITHDRAWN February 2020 Link Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Pe-2 20): Ingenol mebutate get (Picato *) suspension of the licence due to risk of skin malignancy In line with GMMMG / NHSE	ead lice (DNP) OTC	in line with GMMMG / NHSE
in line with GMMMG / NHSE color Col	(DNP)	
in line with GMMMG / NHSE addown cream. Zorinavis cold sore cream agenol mebutate WITHDRAWN February 2020 carlo® 150 microgramsig gel (fice & scale): 500 microgramsig gel (trusk & extensities) MMC HRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato ▼): suspension of the licence due to risk of skin malignancy HRA Drug Safety Update (Oct-19): Ingenol mebutate gel (Picato ▼): increased incidence of skin tumours seen in some clinical studies anolin cream (CMP) OTC In line with GMMMG BNF CMC> In line with GMMMG / NHSE	doxuridine in dimethyl sulfoxide (DNP)	
In line with GMMMG / NHSE	nfrequent cold sores of the lip (DNP) OTC	in line with GMMMG / NHSE
HRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato V): increased incidence due to risk of skin malignancy HRA Drug Safety Update (Cot-19): Ingenol mebutate gel (Picato V): increased incidence of skin tumours seen in some clinical studies annolin cream (DNP)	ngenol mebutate	
in line with GMMMG graph of the control of the con	IHRA Drug Safety Update (Feb-20): Ingenol mebutate gel (Picato ▼): suspension of the licence due to risk of skin mal	
in line with GMMMG / NHSE filled dry skin or irritant dermatitis (DNP) in line with GMMMG / NHSE fillinocycline (CNP) fillinocycline (CNP) in line with GMMMG blets; capsules; MR capsules in line with GMMMG in line with GMMMG / NHSE fillinoxidil (CNP) fillinoxidil (CNP) in line with GMMMG / NHSE fillinoxidil (CNP) thaneous foam appy rash (CNP) orc g. barrier preparations (Sudocrem®, Metanium®) foldassium hydroxide (CNP) in line with GMMMG / NHSE in line with GMMMG / NHSE in line with GMMMG / NHSE fillinoxidil (CNP) orc g. barrier preparations (Sudocrem®, Metanium®) fordassium hydroxide fordiavine cream, BPC DISCONTINUED	anolin cream (DNP) OTC	in line with GMMMG
In line with GMMMG / NHSE	g. Lansinoh HPA fild acne (DNP)	
in line with GMMMG blets; capsules; M/R capsules finor burns and scalds (DNP) in line with GMMMG / NHSE finoxidil (DNP) in line with GMMMG / NHSE traneous foam fappy rash (DNP) orc g, barrier preparations (Sudocrem®, Metanium®) rotassium hydroxide (DNP) fortal vine with GMMMG in line with GMMMG / NHSE in line with GMMMG / NHSE fortal vine preparations (Sudocrem®, Metanium®) rotassium hydroxide (DNP) fortal vine cream, BPC DISCONTINUED	fild dry skin or irritant dermatitis	in line with GMMMG / NHSE
In line with GMMMG / NHSE	finocycline (DNP)	
in line with GMMMG / NHSE Itaneous foam Italeous foam Itaneous foam Itale Itaneous foam It	linor burns and scalds	
in line with GMMMG / NHSE g. barrier preparations (Sudocrem®, Metanium®) otassium hydroxide (IDNP) obliuDab® 5% topical solution roflavine cream, BPC in line with GMMMG DISCONTINUED	(DNP)	
otassium hydroxide (DNP) colluDab® 5% topical solution roflavine cream, BPC DISCONTINUED	appy rash (DNP) OTC	
roflavine cream, BPC DISCONTINUED	otassium hydroxide (DNP)	in line with GMMMG
	Proflavine cream, BPC	

Skin

Ringworm / Athlete's foot (DNP) OTC	in line with GMMMG / NHSE
Topical preparations containing miconazole, clotrimazole, etc	
Silk garments (DNP)	in line with GMMMG / NHSE
including Dermasilk®, Dreamskin®, Skinnies Silk®	
Sun protection (DNP) OTC	in line with GMMMG / NHSE
Sunburn due to excessive sun exposure (DNP) OTC E.g. emollients, oral and topical antihistamines, analgesics	in line with GMMMG / NHSE
Warts and verrucae (DNP) OTC	in line with GMMMG / NHSE
Salicylic acid-containing products, glutaraldehyde	

Section 14: Immunological products & vaccines | Supported by the formulary (click here)



14.4 Vaccines & antisera

Bacillus Calmette-Guérin (BCG) vaccines

Botulism antitoxin

COVID-19 vaccine

Diphtheria vaccines (children under 10yrs old)

Diphtheria vaccines (children over 10yrs old & adults)

Haemophilus type B conjugate vaccine

Hepatitis A vaccine

Hepatitis B vaccine

Human papilloma virus vaccine

Influenza vaccine

Measles, Mumps & Rubella (MMR) vaccine

Meningococcal vaccines

Pneumococcal vaccines

Poliomyelitis vaccines

Rabies vaccines

Respiratory syncytial virus (RSV) vaccine

Tetanus vaccines

Typhoid vaccines

Varicella-zoster vaccines

14.5 Immunoglobulins

14.5.1 Normal immunoglobulin

14.5.2 Disease-specific immunoglobulins

14.5.3 Anti-D (Rh₀) immunoglobulin

Non-Formulary Items

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Guidelines for the Prescribing and Administration of Intravenous Immunoglobulin

Immunoglobulin follow up form

Immunoglobulin Prescribing and Administration Guidelines

Immunoglobulin Prescribing Flow Chart

Immunoglobulin request form

National Demand Programme for Immunoglobulin - Clinical Info

Non-formulary Conversion Table

NICE Guidance

Pregnancy - routine anti-D prophylaxis for rhesus negative women (TA156)

GMMMG Formulary

Formulary Homepage

Chapter 14: Immunological products & vaccines

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List


Other Links

National Immunoglobulin Database

DH: Clinical guidelines for immunoglobulin use (2nd edition update)

Immunoglobulin handbook (HPA)

14.4 Vaccines & antisera		GMMMG
MHRA Drug Safety Update (Apr-16): Live attenuated vaccines: avoid use in those who are clinically immunos	suppressed	
Bacillus Calmette-Guérin (BCG) vaccines		Tuberculosis: the Green Book, ch.32
Bacillus Calmette-Guérin (BCG) vaccine		
injection	BNF emco	
BCG vaccine diagnostic agent (Tuberculin purified protein derivative (PPD))	<u> </u>	
injection	PNE OMCO	
Botulism antitoxin	BNF emc	4
Botulism antitoxin		RESTRICTED
	CHINDS .	Emergencies only
	(5)IN.IP for children	Emergencies only
injection	BNF emc	CaviddOr Aba Cream Baalt, ab 44a
COVID-19 vaccine		Covid19: the Green Book, ch.14a
Pfizer-BioNTech COVID-19 vaccine (Tozinameran / Famtozinameran)		12 years of age and older
	BING for children	
Comirnaty® Original/Omicron BA.4-5 (15/15 micrograms)/dose (GREY cap)	BNF emc	pending availability of XBB1.5
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		12 years of age and older
	BNF	j ca. o or ago arra oraci
Comirnaty® Omicron XBB.1.5 - 30micrograms/dose injection (GREY cap)	BNF emc	
Pfizer-BioNTech COVID-19 vaccine (Raxtozinameran)		5 to 11 year olds
		5 to 11 year olds
Comirnaty® Omicron XBB.1.5 - 10micrograms/dose injection (BLUE cap)	BNF emc	
MHRA Drug Safety Update (Mar-23): COVID-19 vaccines: updates for March 2023		
MHRA Drug Safety Update (Feb-23): COVID-19 vaccines: updates for February 2023		
MHRA Drug Safety Update (Jan-23): COVID-19 vaccines: updates for January 2023		
MHRA Drug Safety Update (Dec-22): COVID-19 vaccines: updates for December 2022		
MHRA Drug Safety Update (Nov-22): COVID-19 vaccines: updates for November 2022		
MHRA Drug Safety Update (Oct-22): COVID-19 vaccines: updates for October 2022 MHRA Drug Safety Update (Sep-22): COVID-19 vaccines: updates for September 2022		
MHRA Drug Safety Update (Aug-22): COVID-19 vaccines: updates for August 2022		
MHRA Drug Safety Update (Jul-22): COVID-19 vaccines: updates for July 2022		
MHRA Drug Safety Update (Jun-22): COVID-19 vaccines: updates for June 2022		
MHRA Drug Safety Update (May-22): COVID-19 vaccines: updates for May 2022		
MHRA Drug Safety Update (Apr-22): COVID-19 vaccines: updates for April 2022		
MHRA Drug Safety Update (Mar-22): COVID-19 vaccines: updates for March 2022		
MHRA Drug Safety Update (Feb-22): COVID-19 vaccines: updates for February 2022 MHRA Drug Safety Update (Jan-22): COVID-19 vaccines: updates for January 2022		
MHRA Drug Safety Update (Dec-21): COVID-19 vaccines: updates for December 2021		
MHRA Drug Safety Update (Nov-21): COVID-19 vaccines: updates for November 2021		
MHRA Drug Safety Update (Oct-21): COVID-19 vaccines: updates for October 2021		
MHRA Drug Safety Update (Sep-21): COVID-19 vaccines: updates for September 2021		
MHRA Drug Safety Update (Aug-21): COVID-19 vaccines: updates for August 2021		
MHRA Drug Safety Update (Jul-21): COVID-19 vaccines: updates for July 2021		
MHRA Drug Safety Update (Jun-21): COVID-19 vaccines: updates for June 2021 MHRA Drug Safety Update (May-21): COVID-19 vaccines: updates for May 2021		
MHRA Drug Safety Update (Feb-21): COVID-19 vaccines and medicines: updates for February 2021		
MHRA Drug Safety Update (Jan-21): COVID-19 vaccines (Pfizer/BioNTech and COVID-19 Vaccine AstraZer	neca): current advice	
MHRA (Dec-20): Regulatory approval of Pfizer/BioNTech vaccine for COVID-19		
Diphtheria vaccines (children under 10yrs old)		Diptheria: the Green Book, ch.15
Infanrix hexa®		
	[8][8]	
injection	BNF emc	
Infanrix-IPV®		
injection	BNF emco	
Repevax®	EIIIC	7
T	e)Nie.	
injection	(CO) Num for children	
injection Diphthoria vaccines (children ever 10 yrs old 1 adults)	BNF emc	Dinthorio: the Green Beak, sh.45
Diphtheria vaccines (children over 10yrs old & adults)		Diptheria: the Green Book, ch.15
Revaxis®		
	(S)NUS for shildren	
injection	BNF emc	



14.5 Immunoglobulins



- **2.)** MFT have adopted a 'no form, no immunoglobulin' policy. All IVIg requests must have an Immunoglobulin Request Form completed via Hive.
- 3.) All immunoglobulin use MUST be recorded on the National Immunoglobulin Database.

14.5.1 Normal immunoglobulin RED	(for ITP & home treatment programmes)	G⋈ <mark>M</mark> MG
For intramuscular use		
Normal immunoglobulin injection ED		RESTRICTED Specialist use only
For subcutaneous use	PbR X BNF emco)
Normal immunoglobulin injection RED (f) injection	PBR X MMC BNF (emcs)	RESTRICTED Specialist use only
For intravenous use		
Human normal immunoglobulin		RESTRICTED Specialist use only
injection	PBRX MMC BNF emco	
14.5.2 Disease-specific immunoglobulins		G^MMG
Hepatitis B immunoglobulin		
Hepatitis B immunoglobulin		RESTRICTED Not Stocked
injection	BNF emc)
Tetanus immunoglobulin Tetanus immunoglobulin		
injection	BNF emc®	
Varicella-Zoster immunoglobulin		4
Varicella-Zoster immunoglobulin GREEN injection	BNF emc	RESTRICTED Not Stocked
Cytomegalovirus (CMV) immunoglobulin		
Human normal immunoglobulin (CMV)	EVN E	RESTRICTED Specialist use only
injection	MMC BNF emc	
14.5.3 Anti-D (Rh ₀) immunoglobulin		GM <mark>M</mark> MG
Anti-D (Rh ₀) immunoglobulin		
RED		
injection	NICE MMC BNF @mc®	

Non-Formulary Items	GMMMG
AstraZeneca COVID-19 vaccine	DISCONTINUED
	May 2024
Vaxzevria® injection	MMC BNF emc⊕
Moderna Biotech COVID-19 vaccine	DIGGONTINUED
	DISCONTINUED
Spikevax® injection	MMC BNF emco
Novavax COVID-19 vaccine	MINO BINE CITICO
NOTATION TO THE TO THE CONTROL	PAUSED by JCVI
<i>Nuvaxovid</i> ® injection	MMC BNF emc®
Pediacel®	REPLACED by
	Infanrix hexa®
njection	BNF emc⊚
Infanrix-IPV+Hib®	REPLACED by
	Infanrix hexa®
	IIIIaiiiix iiexaw
njection	BNF emco

Section 15: Anaesthesia

Supported by the formulary (click here)



15.1 General anaesthesia

15.1.1 Intravenous anaesthetics

15.1.2 Inhalational anaesthetics

15.1.3 Antimuscarinic drugs

15.1.4 Sedative & analgesic post-operative drugs

15.1.4.1 Benzodiazepines

15.1.4.2 Non-opioid analgesics

15.1.4.3 Opioid analgesics

15.1.4.4 Other drugs for sedation

15.1.5 Neuromuscular blocking drugs

Non-depolarising neuromuscular blocking drugs

Depolarising neuromuscular blocking drugs

15.1.6 Drugs for reversal of neuromuscular blockade

Anticholinesterases

Other drugs for reversal of neuromuscular blockade

15.1.7 Antagonists for central & respiratory depression

15.1.8 Drugs for malignant hyperthermia

15.2 Local anaesthesia

Lidocaine

Bupivacaine

Levobupivacaine

Prilocaine

Ropivacaine

Tetracaine

Local Anaesthetic Toxicity

Othe<u>r agents</u>

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)

PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Paediatric Anaesthesia Website

Children's Pain Management Website

PICU Emergency Drugs Calculator

Non-formulary Conversion Table

NICE Guidance

Sedation in under 19s: using sedation for diagnostic and therapeutic procedures (CG112)


GMMMG Formulary


Formulary Homepage

Chapter 15: Anaesthesia (ON HOLD)


GMMMG Adult Red/Amber/Green; DNP and Grey Drug List

GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List





45 0 Landons th		A A O DI GA E E EVI GAMBIEL ME
15.2 Local anaesthesia		AAGBI SAFETY GUIDELINE
5.2 Local anaesthesia		
idocaine hydrochloride		
idocaine	BNF	
5%, 1% & 2% injection (see also section 2.3.2)	BNF emco	
vith adrenaline		
idocaine with adrenaline		
	IE/WIE	
%, 2% injection	BNF emc	
or surface anaesthesia		
idocaine with chlorhexidine		
nstillagel® 2% gel	PNE Amc	
Lidocaine	BNF emc	
Datifula Astina CHC From 20/ and	ama ama	
OptiLube Active CHG Free® 2% gel Lidocaine with phenylephrine	BNF emc	
Cambanylagina @ 50/ 10 50/ or	BNE	
Co-phenylcaine ® 5% / 0.5% spray Lidocaine with prilocaine	MMC BNF emc	
Liacoanie with prinocallie		
TAM A O FO	ES N F	
EMLA® 5% cream	(BNF) (emc⊚	
Lidocaine		
	SX N I F	
1% topical solution	BNF emc	
Lidocaine		
	ESIN III	
.aryngojet® 4% (160mg/4mL) jet spray	BNF emc	
Lidocaine		
5% ointment	BNF emc	
Lidocaine		
	EXXII	
Kylocaine® 10% spray	BNF emc	
Lidocaine		RESTRICTED
GREY GREEN		Specialist pain team only
/ersatis® 700mg medicated plaster	MMC BNF emc	for in-patient use - not for discharg
Bupivacaine hydrochloride		
Bupivacaine hydrochloride		
	B) N F	
0.25% Infusion (500mL)	BNF emc	
Bupivacaine hydrochloride with glucose		
	BINIS	
Marcain Heavy ® 0.5% Injection	BNF emc	
with adrenaline		
Bupivacaine and adrenaline		
0.25% with 1:200,000 injection	BNF emc	
Bupivacaine and adrenaline		
0.5% with 1:200,000 injection	BNF emc	
vith other ingredients		
Bupivacaine and fentanyl		
<u> </u>		
 0.125% with 1mg/500mL infusion	(BNF) emc	
Bupivacaine and sodium chloride	SM SINCE	
•	IndoN III	
0.08% in 0.9%	BNF emc	
Bupivacaine hydrochloride with glucose	BNF GIIICO	
-ap. a.a injuredinariae maii giuoode	Constitution in the Consti	
10mg with 200mg/Aml, apinglists-time	ESNIF occurre	
20mg with 320mg/4mL spinal injection	BNF emc	



MFT Formulary v10.5 (May 2025) Section 16 Miscellaneous

Section 16: Miscellaneous



16.1 Organ Perfusion Fluids

- 16.1.1 Cardiac Perfusion Fluids 16.1.2 Kidney / Pancreas / Liver perfusion fluids
- 16.1.3 Contrast Agents
- 16.1.4 Hydrogen / Methane breath tests

ADULT - medicine & prescribing policies / guidelines (MFT Policy Hub)
PAEDIATRIC - medicine & prescribing policies / guidelines (MFT Policy Hub)

NEONATAL - medicine & prescribing policies / guidelines (MFT Policy Hub)

Non-formulary Conversion Table

NICE Guidance

Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

GMMMG Formulary

Formulary Homepage

GMMMG Adult Red/Amber/Green; DNP and Grey Drug List GMMMG Paediatric Red/Amber/Green; DNP and Grey Drug List

16.1 Organ Perfusion fluids			
16.1.1 Cardiac perfusion fluids			
Aspartate / Glutamate solution			
100mL	MMC		
Bretschneiders Histidine-Trytophan-Ketoglutarate (HTK)	1011010		
, , , , , , , , , , , , , , , , , , ,			
Custodiol Cardioplegia® solution (1000mL)	BARAO	ama a	
Cardioplegia in Ringer's solution	MMC	<u>emc</u>	
Caralopiogia in Tangor o Solution			
4000	2424		
Cardioplegic ULTH Formula A	MMC	<u>emc</u> ⊕	
Cardiopiegic of TTT official A			
500mL	MMC		
Cardioplegic ULTH Formula B			
500mL	MMC		
Sterile Concentrate for Cardioplegia infusion			
20mL	MMC	emc⊕	
16.1.2 Kidney / Pancreas / Liver perfusion fluids			
Cold Storage Solution (UW solution)			
Belzer UW® (1000mL)	MMC		
Kidney Perfusion Fluid			
	MMC		
Lung Perfusion solution	101101		
Perfadex® (1000mL)	MMC		
Machine Perfusion solution	MINIC		
D. (84840		
Belzer MPS® UW machine perfusion solution (1000mL) 16.1.3 Contrast Agents	MMC		
Gadobutrol			
Cauchano			
Codeviet® (4 Ocean aller) bisingting	84840		
Gadovist® (1.0mmol/mL) injection Gadoteric acid	MMC	emc⊕	
Caudiend acid			
D () () () () () ()			
Dotarem ® (0.5mmol/mL) injection Gadoxetic acid		<u>emc</u>	
Gadoxetic acid			
Primovist® (0.25mmol/mL) injection	MMC	<u>emc</u> ⊕	
Perflutren			
Luminity ® (150microlitres/mL) lipid microspheres for injection	MMC	<u>emc</u> ⊚	
Sulphur hexafluoride			
SonoVue® (8microlitre/mL) injection	MMC	emc⊕	
16.1.4 Hydrogen / Methane breath tests			
Fructose, Glucose, Lactose and Lactulose U			RESTRICTED Gastro. only in line with
		 ≢ESPGHAN	ESPGHAN guidelines
powder	MMC	emca	